

List of Publications by the VIVIT

Table of Content

Original Papers, Cardiometabolic Disease.....	2
Original Papers, Oncology	19
Original Papers, Nephrology.....	21
Original Papers, <i>In Vitro</i> Studies.....	26
Original Papers, Other Research Areas	26
Case Reports.....	30
Reviews.....	31
Guidelines, Position Papers, Recommendations.....	36
Letters, Editorials.....	44
Clinical Trials.....	45
Other Articles	51

Original Papers, Cardiometabolic Disease

1. Brandtner EM, Leiherer A, Larcher B, Geiger K, Heinzle C, Schnetzer L, Saely CH, Drexel H, Muendlein A. Angiotensin-like protein 2 and mortality in patients with heart failure-Results from an observational study. *Eur J Clin Invest*. 2025 Nov 3:e70143. doi: 10.1111/eci.70143. Epub ahead of print. PMID: 41181893
2. Leiherer A, Schnetzer L, Mink S, Mader A, Mündlein A, Bermeitinger B, Moissl-Blanke AP, März W, Hammerer-Lercher A, Kleber ME, Drexel H. Interpretable type 2 diabetes incidence prediction with AutoScore: A model based on standard clinical parameters. *Int J Med Inform*. 2025 Oct 18;206:106161. doi: 10.1016/j.ijmedinf.2025.106161. Epub ahead of print. PMID: 41176846.
3. Schnetzer L, Muendlein A, Festa A, Saely CH, Drexel H, Leiherer A. Sex-Specific Disparities in Lipid-Based Prediction of Major Cardiovascular Events. *Eur J Prev Cardiol*. 2025 Oct 8:zwaf646. doi: 10.1093/eurjpc/zwaf646. Epub ahead of print. PMID: 41058584.
4. Muendlein A, Leiherer A, Brandtner EM, Heinzle C, Geiger K, Gaenger S, Schnetzer L, Festa A, Saely CH, Drexel H. Leucine-rich α -2 glycoprotein 1 is associated with increased mortality risk in patients with peripheral artery disease. *J Mol Med (Berl)*. 2025 Oct 6. doi: 10.1007/s00109-025-02602-4. Epub ahead of print. PMID: 41051413.
5. Muendlein A, Leiherer A, Brandtner EM, Geiger K, Heinzle C, Gaenger S, Schnetzer L, Festa A, Saely CH, Drexel H. Serum leucine-rich α -2 glycoprotein 1 predicts 10-year mortality and vascular events in coronary angiography patients. *Atherosclerosis*. 2025 Aug;407:120413. doi: 10.1016/j.atherosclerosis.2025.120413. Epub 2025 Jun 20. PMID: 40577971.
6. Mader A, Haeberli D, Larcher B, Dopheide JF, Saely CH, Heinzle CF, Amann P, Schindewolf M, Festa A, Drexel H. Contribution of type 2 diabetes to major adverse cardiovascular events (MACE) in a long-term observational study with different stages of atherosclerosis. *Sci Rep*. 2025 Jan 22;15(1):2792. doi: 10.1038/s41598-024-84985-x. PMID: 39843486; PMCID: PMC11754429.
7. Schnetzer L, Leiherer A, Festa A, Mündlein A, Plattner T, Mayer G, Saely C, Drexel H. Type 2 diabetes and chronic kidney disease as long-term predictors of cardiovascular events in patients with coronary artery disease. *Eur J Clin Invest*. 2025 Mar;55(3):e14374. doi: 10.1111/eci.14374. Epub 2024 Dec 20. PMID: 39704124
8. Neyer M, Vogel JB, Elsner P, Kuehrer H, Saely CH, Muendlein A, Vonbank A, Mader A, Festa A, Drexel H, Leiherer A. Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis. *Diabetes Obes Metab*. 2025 Feb;27(2):835-844. doi: 10.1111/dom.16084. Epub 2024 Nov 27. PMID: 39604296.
9. Drexel H, Mader A, Larcher B, Festa A, Vonbank A, Fraunberger P, Leiherer A, Saely CH. Remnant cholesterol and long-term incidence of death in coronary artery disease patients.

- Atherosclerosis. 2025 Feb;401:119048. doi: 10.1016/j.atherosclerosis.2024.119048. Epub 2024 Nov 16. PMID: 39632214.
10. Leiherer A, Muendlein A, Mink S, Mader A, Saely CH, Festa A, Fraunberger P, Drexel H. Machine Learning Approach to Metabolomic Data Predicts Type 2 Diabetes Mellitus Incidence. *Int J Mol Sci*. 2024 May 14;25(10):5331. doi: 10.3390/ijms25105331
 11. Vogel JB, Neyer M, Elsner P, Vonbank A, Plattner T, Saely CH, Leiherer A, Drexel H. Current Practices of Medication Plans in Austrian Patients Undergoing Coronary Angiography: An In-Depth Analysis. *J Clin Med*. 2024 May 29;13(11):3187. doi: 10.3390/jcm13113187.
 12. Ratz M, Vogel JB, Kühner H, Säly CH, Mündlein A, Vonbank A, Mader A, Fraunberger P, Leiherer A, Drexel H. 25 years of lipid-lowering therapy: secular trends in therapy of coronary patients. *Wien Klin Wochenschr*. 2024 May 14. doi: 10.1007/s00508-024-02365-x.
 13. Leiherer A, Brozek W, Muendlein A, Ulmer H, Saely CH, Fraunberger P, Nagel G, Zitt E, Drexel H, Concin H. The value of earlier-in-life systolic and diastolic blood pressure for cardiovascular risk prediction. *iScience*. 2024 Feb 2;27(3):109097. doi: 10.1016/j.isci.2024.109097.
 14. Leiherer A, Muendlein A, Saely CH, Laaksonen R, Fraunberger P, Drexel H. Ceramides improve cardiovascular risk prediction beyond low-density lipoprotein cholesterol. *Eur Heart J Open*. 2024 Jan 8;4(1):oeae001. doi: 10.1093/ehjopen/oeae001
 15. Muendlein A, Heinzle C, Leiherer A, Brandtner EM, Geiger K, Gaenger S, Fraunberger P, Mader A, Saely CH, Drexel H. Circulating glypican-4 is a new predictor of all-cause mortality in patients with heart failure. *Clin Biochem*. 2023 Nov;121-122:110675. doi: 10.1016/j.clinbiochem.2023.110675. Epub 2023 Oct 14. PMID: 37844682.
 16. Leiherer A, Muendlein A, Saely CH, Geiger K, Brandtner EM, Heinzle C, Gaenger S, Mink S, Laaksonen R, Fraunberger P, Drexel H. Coronary Event Risk Test (CERT) as a Risk Predictor for the 10-Year Clinical Outcome of Patients with Peripheral Artery Disease. *J Clin Med*. 2023 Sep 23;12(19):6151. doi: 10.3390/jcm12196151. PMID: 37834795; PMCID: PMC10573503.
 17. Xu Y, Derakhshan A, Hysaj O, Wildisen L, Ittermann T, Pingitore A, Abolhassani N, Medici M, Kiemeny LALM, Riksen NP, Dullaart RPF, Trompet S, Dörr M, Brown SJ, Schmidt B, Führer-Sakel D, Vanderpump MPJ, Muendlein A, Drexel H, Fink HA, Ikram MK, Kavousi M, Rhee CM, Bensenor IM, Azizi F, Hankey GJ, Iacoviello M, Imaizumi M, Ceresini G, Ferrucci L, Sgarbi JA, Bauer DC, Wareham N, Boelaert K, Bakker SJL, Jukema JW, Vaes B, Iervasi G, Yeap BB, Westendorp RGJ, Korevaar TIM, Völzke H, Razvi S, Gussekloo J, Walsh JP, Cappola AR, Rodondi N, Peeters RP, Chaker L; Thyroid Studies Collaboration. The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis. *Lancet Diabetes Endocrinol*. 2023

- Oct;11(10):743-754. doi: 10.1016/S2213-8587(23)00227-9. Epub 2023 Sep 8. PMID: 37696273
18. Adam L, Strickler E, Borozadi MK, Bein S, Bano A, Muka T, Drexel H, Dopheide JF. Prognostic Role of Polyvascular Involvement in Patients with Symptomatic Peripheral Artery Disease. *J Clin Med*. 2023 May 11;12(10):3410. doi: 10.3390/jcm12103410. PMID: 37240515; PMCID: PMC10219171
 19. Muendlein A, Heinzle C, Leiherer A, Geiger K, Brandtner EM, Gaenger S, Fraunberger P, Saely CH, Drexel H. Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease. *Int J Cardiol*. 2022 Dec 15;369:54-59. doi: 10.1016/j.ijcard.2022.08.018. Epub 2022 Aug 6. PMID: 35944770
 20. Dopheide JF, Gillmann P, Spirk D, Khorrami Borozadi M, Adam L, Drexel H. False versus True Statin Intolerance in Patients with Peripheral Artery Disease. *J Clin Med*. 2022 Nov 8;11(22):6619. doi: 10.3390/jcm11226619. PMID: 36431097; PMCID: PMC9695369
 21. Kaspar M, Bott A, Rastan A, Dopheide JF, Drexel H, Schindewolf M. Preoperative Factors Associated with Target Lesion Revascularization following Endovascular Therapy of the Superficial Femoral Artery. *J Clin Med*. 2022 Aug 8;11(15):4606. doi: 10.3390/jcm11154606. PMID: 35956221; PMCID: PMC9369774
 22. Muendlein A, Brandtner EM, Leiherer A, Geiger K, Heinzle C, Gaenger S, Fraunberger P, Haider D, Saely CH, Drexel H. Evaluation of the association of serum glypican-4 with prevalent and future kidney function. *Sci Rep*. 2022 Jun 17;12(1):10168. doi: 10.1038/s41598-022-14306-7. PMID: 35715556; PMCID: PMC9206029
 23. Silbernagel G, Scharnagl H, Saely CH, Reinthaler M, Rief M, Kleber ME, Larcher B, Chapman J, Schaefer JR, Drexel H, März W. The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs. *Biomedicines*. 2022 Jun 2;10(6):1302. doi: 10.3390/biomedicines10061302. PMID: 35740324; PMCID: PMC9220033
 24. Leiherer A, Mündlein A, Laaksonen R, Lääperi M, Jylhä A, Fraunberger P, Drexel H. Comparison of recent ceramide-based coronary risk prediction scores in cardiovascular disease patients. *Eur J Prev Cardiol*. 2022 May 6;29(6):947-956. doi: 10.1093/eurjpc/zwab112. PMID: 34417607
 25. Muendlein A, Brandtner EM, Leiherer A, Geiger K, Heinzle C, Gaenger S, Fraunberger P, Mader A, Saely CH, Drexel H. Data on the association of serum glypican-4 with future major adverse cardiovascular events and mortality in patients undergoing coronary angiography. *Data Brief*. 2022 Apr 9;42:108142. doi: 10.1016/j.dib.2022.108142. PMID: 35496482; PMCID: PMC9046629

26. Muendlein A, Brandtner EM, Leiherer A, Geiger K, Heinzle C, Gaenger S, Fraunberger P, Mader A, Saely CH, Drexel H. Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients. *Atherosclerosis*. 2022 Mar;345:33-38. doi: 10.1016/j.atherosclerosis.2022.02.015. Epub 2022 Feb 13. PMID: 35202959
27. Saely CM, Maechler M, Vonbank A, Sprenger L, Mader A, Larcher B, Zanolin-Purin D, Leiherer A, Muendlein A, Drexel H. Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria: Data from subgroup analysis and data on moderate albuminuria. *Data Brief*. 2022 Jan 10;40:107817. doi: 10.1016/j.dib.2022.107817. PMID: 35071710; PMCID: PMC8762350
28. Annema W, Gawinecka J, Muendlein A, Saely CH, Drexel H, von Eckardstein A. Elevated levels of apolipoprotein D predict poor outcome in patients with suspected or established coronary artery disease. *Atherosclerosis*. 2022 Jan;341:27-33. doi: 10.1016/j.atherosclerosis.2021.12.011. Epub 2021 Dec 20. PMID: 34959206
29. Yazdani B, Delgado GE, Scharnagl H, Krämer BK, Drexel H, März W, Scherberich JE, Leiherer A, Kleber ME. Combined Use of Serum Uromodulin and eGFR to Estimate Mortality Risk. *Front Med (Lausanne)*. 2021 Sep 8;8:723546. doi: 10.3389/fmed.2021.723546. PMID: 34568379; PMCID: PMC8455921
30. Drexel H, Mader A, Saely CH, Tautermann G, Dopheide JF, Vonbank A. Downhill hiking improves low-grade inflammation, triglycerides, body weight and glucose tolerance. *Sci Rep*. 2021 Jul 15;11(1):14503. doi: 10.1038/s41598-021-93879-1. PMID: 34267272; PMCID: PMC8282605
31. Dopheide JF, Veit J, Ramadani H, Adam L, Papac L, Vonbank A, Kaspar M, Rastan A, Baumgartner I, Drexel H. Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease. *Eur Heart J Cardiovasc Pharmacother*. 2021 Jul 23;7(4):263-270. doi: 10.1093/ehjcvp/pvz081. PMID: 31886861
32. Leiherer A, Ulmer H, Muendlein A, Saely CH, Vonbank A, Fraunberger P, Foeger B, Brandtner EM, Brozek W, Nagel G, Zitt E, Drexel H, Concin H. Value of total cholesterol readings earlier versus later in life to predict cardiovascular risk. *EBioMedicine*. 2021 May;67:103371. doi: 10.1016/j.ebiom.2021.103371. Epub 2021 May 14. PMID: 34000625; PMCID: PMC8138461
33. Dopheide JF, Adam L, Wiedmer S, Kaspar M, Silbernagel G, Baumgartner I, Drexel H. Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease. *Curr Vasc Pharmacol*. 2021;19(6):634-642. doi: 10.2174/157016111966621011123621. PMID: 33430734
34. Saely CH, Maechler M, Vonbank A, Sprenger L, Mader A, Larcher B, Zanolin- Purin D, Leiherer A, Muendlein A, Drexel H. Single and joint impact of type 2 diabetes and of

- congestive heart failure on albuminuria. *J Diabetes Complications*. 2021 Dec;35(12):108046. doi: 10.1016/j.jdiacomp.2021.108046. Epub 2021 Sep 12. PMID: 34598838
35. Sprenger L, Mader A, Larcher B, Mächler M, Vonbank A, Zanolin-Purin D, Leiherer A, Muendlein A, Drexel H, Saely CH. Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease. *BMJ Open Diabetes Res Care*. 2021 Nov;9(2):e002407. doi: 10.1136/bmjdr-2021-002407. PMID: 34782334; PMCID: PMC8593703
36. Leiherer A, Mündlein A, Brandtner EM, Säly CH, Ramadan H, Vonbank A, Mader A, Dopheide JF, Jylhä A, Lääperi M, Laaksonen R, März W, Fraunberger P, Kleber M, Drexel H. Lipid profiles of patients with manifest coronary versus peripheral atherosclerosis - Is there a difference? *J Intern Med*. 2021 Dec;290(6):1249-1263. doi: 10.1111/joim.13368. Epub 2021 Sep 10. PMID: 34337800
37. Brandtner EM, Muendlein A, Leiherer A, Armbruster FP, Dschietzig TB, Geiger K, Fraunberger P, Saely CH, Drexel H. Serum Parathyroid Hormone Predicts Mortality in Coronary Angiography Patients with Type 2 Diabetes. *J Clin Endocrinol Metab*. 2020 Nov 1;105(11):dgaa512. doi: 10.1210/clinem/dgaa512. PMID: 32785694
38. Saely CH, Sternbauer S, Vonbank A, Heinzle C, Zanolin-Purin D, Larcher B, Mader A, Leiherer A, Muendlein A, Drexel H. Type 2 diabetes mellitus is a strong predictor of LDL cholesterol target achievement in patients with peripheral artery disease. *J Diabetes Complications*. 2020 Nov;34(11):107692. doi: 10.1016/j.jdiacomp.2020.107692. Epub 2020 Jul 28. PMID: 32878717
39. Larcher B, Zanolin-Purin D, Vonbank A, Heinzle CF, Mader A, Sternbauer S, Drexel H, Saely CH. Usefulness of Handgrip Strength to Predict Mortality in Patients With Coronary Artery Disease. *Am J Cardiol*. 2020 Aug 15;129:5-9. doi: 10.1016/j.amjcard.2020.05.006. Epub 2020 May 16. PMID: 32580913
40. Dopheide JF, Ramadan H, Adam L, Gahl B, Papac L, Veit J, Kaspar M, Schindewolf M, Baumgartner I, Drexel H. Development of a 3-Dimensional Prognostic Score for Patients With Symptomatic Peripheral Artery Disease: PAD^{3D} Score. *Angiology*. 2020 Aug;71(7):658-665. doi: 10.1177/0003319720920155. Epub 2020 Apr 28. PMID: 32342699
41. Dopheide JF, Ramadan H, Adam L, Gahl B, Papac L, Veit J, Kaspar M, Schindewolf M, Baumgartner I, Drexel H. Development of a 3-Dimensional Prognostic Score for Patients with Symptomatic Peripheral Artery Disease: PAD 3D Score. *Angiology* 2020 Apr 28
42. Breyer MK, Offenheimer A, Altziebler J, Hartl S, Burghuber OC, Studnicka M, Purin D, Heinzle C, Drexel H, Franssen FME, Wouters EFM, Harreiter J, Kautzky-Willer A, Breyer-Kohansal R. Marked differences in prediabetes- and diabetes- associated comorbidities between men and women-Epidemiological results from a general population-based cohort aged 6-

- 80 years-The LEAD (Lung, hEart, sociAl, boDy) study. *Eur J Clin Invest.* 2020 Mar;50(3):e13207. doi: 10.1111/eci.13207. Epub 2020 Feb 12. PMID: 31997311
43. Breyer MK, Offenheimer A, Altziebler J, Hartl S, Burghuber OC, Studnicka M, Purin D, Heinzle C, Drexel H, Franssen FME, Wouters EFM, Harreiter J, Kautzky-Willer A, Breyer-Kohansal R. Marked Differences in Prediabetes- And Diabetes-Associated Comorbidities Between Men and women-Epidemiological Results from a General Population-Based Cohort Aged 6-80 years-The LEAD (Lung, hEart, sociAl, boDy) Study *Eur J Clin Invest.* 2020 Mar;50(3):e13207
 44. Muendlein A, Geiger K, Leiherer A, Saely CH, Fraunberger P, Drexel H. Evaluation of the associations between circulating microRNAs and kidney function in coronary angiography patients. *Am J Physiol Renal Physiol.* 2020 Feb 1;318(2):F315-F321
 45. Leiherer A, Ebner J, Muendlein A, Brandtner EM, Zach C, Geiger K, Fraunberger P, Drexel H. High betatrophin in coronary patients protects from cardiovascular events. *Atherosclerosis.* 2020 Jan;293:62-68
 46. Leiherer A, Ebner J, Muendlein A, Brandtner EM, Zach C, Geiger K, Fraunberger P, Drexel H. Data on the power of high betatrophin to predict cardiovascular deaths in coronary patients. *Data Brief.* 2019 Dec 12;28:104989. doi: 10.1016/j.dib.2019.104989. eCollection 2020 Feb
 47. Dopheide JF, Veit J, Ramadani H, Adam L, Papac L, Vonbank A, Kaspar M, Rastan A, Baumgartner I, Drexel H. Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease. *Eur Heart J Cardiovasc Pharmacother.* 2019 Dec 10
 48. Haine A, Schmid MJ, Schindewolf M, Lenz A, Bernhard SM, Drexel H, Baumgartner I, Dopheide JF. Comparison Between Interwoven Nitinol and Drug Eluting Stents for Endovascular Treatment of Femoropopliteal Artery Disease. *Eur J Vasc Endovasc Surg.* 2019 Dec;58(6):865-873. doi: 10.1016/j.ejvs.2019.09.002. Epub 2019 Oct 25
 49. Leiherer A, Muendlein A, Saely CH, Fraunberger P, Drexel H. Serotonin is elevated in risk-genotype carriers of TCF7L2 - rs7903146. *Sci Rep.* 2019 Sep 6;9(1):12863
 50. Drexel H, Leiherer A, Saely CH, Brandtner EM, Geiger K, Vonbank A, Fraunberger P, Muendlein A. Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis. *Biosci Rep.* 2019 Aug 7;39(8)
 51. Muendlein A, Leiherer A, Saely C, Ebner J, Geiger K, Brandtner EM, Vonbank A, Fraunberger P, Drexel H. The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events. *Atherosclerosis.* 2019 Jul;286:1-6
 52. Muendlein A, Leiherer A, Saely C, Ebner J, Geiger K, Brandtner EM, Vonbank A, Fraunberger P, Drexel H. Data on the association between CTRP1 and future major adverse cardiovascular events in patients undergoing coronary angiography. *Data Brief.* 2019 Jun 7;25:104109

53. Saely CH, Mader A, Heinzle CF, Zanolin-Purin D, Larcher B, Vonbank A, Drexel H. Diabetes Awareness Among Coronary Artery Disease Patients Is Higher in Women Than in Men. *Diabetes Care*. 2019 Jun;42(6):e87-e88. doi: 10.2337/dc19-0241. Epub 2019 Apr 22
54. Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behloul H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hofer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kilisek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J; CARDIoGRAMPlusC4D Consortium, Van der Harst P, Tardif JC, Sattar N, Lang CC, Pare G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. *Circ Genom Precis Med*. 2019 Apr;12(4):e002471
55. Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloul H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engström T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren

- A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots ML, Brenner H, Bruggs JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hofer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Pare G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW. Subsequent Event Risk in Individuals with Established Coronary Heart Disease. *Circ Genom Precis Med*. 2019 Apr;12(4):e002470. doi: 10.1161/CIRCGEN.119.002470. Epub 2019 Mar 21.
56. Kaspar M, Baumgartner I, Staub D, Drexel H, Thalhammer C. Non-invasive ultrasound-based imaging of atherosclerosis. *Vasa*. 2019 Mar;48(2):126-133
 57. Saely CH, Schindewolf M, Zanolin D, Heinzle CF, Vonbank A, Silbernagel G, Leiberer A, Drexel H, Baumgartner I. Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study. *Atherosclerosis*. 2018 Dec;279:32-37
 58. Saely CH, Schindewolf M, Zanolin D, Heinzle CF, Vonbank A, Silbernagel G, Leiberer A, Drexel H, Baumgartner I. Data on the impact of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events. *Data Brief*. 2018 Nov 3;21:1716-1720
 59. Ferrières J, Lautsch D, Gitt AK, De Ferrari G, Toplak H, Elisaf M, Drexel H, Horack M, Baxter C, Ambegaonkar B, Brudi P, Toth PP. Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol -Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS). *Diabetes Obes Metab*. 2018 Nov;20(11):2670-2674. doi: 10.1111/dom.13415.
 60. Jaeger A, Zollinger L, Saely CH, Muendlein A, Evangelakos I, Nasias D, Charizopoulou N, Schofield JD, Othman A, Soran H, Kardassis D, Drexel H, Eckardstein AV. Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. *Sci Rep*. 2018 Sep 4;8(1):14274.
 61. Dopheide JF, Papac L, Schindewolf M, Baumgartner I, Drexel H. Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. *J Clin Lipidol*. 2018 May - Jun;12(3):711-717

62. Leiherer A, Muendlein A, Saely CH, Brandtner EM, Geiger K, Fraunberger P, Drexel H. The value of uromodulin as a new serum marker to predict decline in renal function. *J Hypertens*. 2018 Jan;36(1):110-118
63. Zeller T, Seiffert M, Müller C, Scholz M, Schäffer A, Ojeda F, Drexel H, Mündlein A, Kleber ME, März W, Sinning C, Brunner FJ, Waldeyer C, Keller T, Saely CH, Sydow K, Thiery J, Teupser D, Blankenberg S, Schnabel R. Genome-Wide Association Analysis for Severity of Coronary Artery Disease Using the Gensini Scoring System. *Front Cardiovasc Med*. 2017 Sep 20;4:57
64. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leiherer A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hoefler IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS; GENIUS-CHD consortium, Krämer BK, Scharnagl H, Fliser D, März W, Speer T. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes Endocrinol*. 2017 Jul;5(7):534-543
65. Fraunberger P, Gröne E, Gröne HJ, Drexel H, Walli AK. Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. *J Inflamm (Lond)*. 2017 Feb 2;14:3.
66. Leiherer A, Muendlein A, Saely CH, Kinz E, Brandtner EM, Fraunberger P, Drexel H. Serum uromodulin is associated with impaired glucose metabolism. *Medicine (Baltimore)*. 2017 Feb;96(5): PMID: 28151855
67. Leiherer A, Muendlein A, Saely CH, Ebner J, Brandtner EM, Fraunberger P, Drexel H. Serum uromodulin is a predictive biomarker for cardiovascular events and overall mortality in coronary patients. *Int J Cardiol*. 2016 Dec 29. pii: S0167-5273(16)32602-X. PMID: 28089453
68. Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B. Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885

- statin-treated patients by country and region across the world. Data Brief. 2016 Sep 29;9:616-620. PMID: 27766290
69. Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. *Atherosclerosis*. 2016 Dec;255:200-209.
 70. Jaeger T, Muendlein A, Hodaie J, Untergasser G, Steurer M, Saely CH, Drexel H, Lang AH. Prevalence of calreticulin exon 9 indel mutations in vascular risk patients. *Thromb Res*. 2016 Aug;144:215-7 PMID: 27423004
 71. Vonbank A, Saely CH, Rein P, Zanolin D, Drexel H. Lipoprotein (a), the Metabolic Syndrome and Vascular Risk in Angiographed Coronary Patients. *JCEM* 2016 Aug;101(8):3199-203.
 72. Saely CH, Leiherer A, Muendlein A, Vonbank A, Rein P, Geiger K, Malin C, Drexel H. Coronary patients with high plasma omentin are at a higher cardiovascular risk. *Data in Brief* 2015; 6:158-61.
 73. Naerr G, Rein P, Saely CH, Drexel D. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. *Vascular Pharmacology* 2016; 81: 22-30.
 74. Mueller DM; Allenspach M, Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. *Atherosclerosis* 2015; 243: 638-644.
 75. Saely CH, Leiherer A, Muendlein A, Vonbank A, Rein P, Geiger K, Malin C, Drexel H. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. *Atherosclerosis* 2016; 244: 38-43.
 76. Leiherer A, Muendlein A, Kinz E, Vonbank A, Rein P, Fraunberger P, Malin C, Saely CH, Drexel H. High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events - Insights from phenotype and genotype characterization. *Vascular Pharmacology* 2016; 77:60-8.
 77. Vonbank A, Saely CH, Rein P, Drexel H. Lipid Parameters in Patients with Acute Coronary Syndromes versus Stable Coronary Artery Disease. *Eur J Clin Invest* 2015; 45: 1092-1097.
 78. Muendlein A, Leiherer A, Saely CH, Rein P, Zanolin D, Kinz E, Brandtner EM, Fraunberger P, Drexel H. Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patients. *Atherosclerosis* 2015; 242: 340-345.
 79. Silbernagel G, Rein P, Saely CH, Engelberger RP, Willenberg T, Do DD, Kucher N, Baumgartner I, Drexel H. Prevalence of Type 2 Diabetes Is Higher in Peripheral Artery Disease than in Coronary Artery Disease Patients. *Diab Vasc Dis Res* 2015; 12: 146-9.

80. Wirth K, Peter RS, Saely CH, Concin H, Nagel G. Long-term weight change: association with impaired glucose metabolism in young austrian adults. *PLoS One* 2015; 10: e0127186.
81. Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A, Hornemann T. Plasma C20- Sphingolipids predict cardiovascular events independently from conventional cardiovascular risk factors in patients undergoing coronary angiography. *Atherosclerosis* 2015; 240: 216-21.
82. Rein P, Saely CH, Vonbank A, Fraunberger P, Drexel H. Is albuminuria a myocardial infarction risk equivalent for atherothrombotic events? *Atherosclerosis*. 2015 May;240(1):21-5. PubMed PMID: 25746373.
83. Othman A, Saely CH, Muendlein A, Vonbank A, Drexel H, von Eckardstein A, Hornemann T. Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus. *BMJ Open Diabetes Research & Care* 2015; 3: e000073.
84. Rein P., Saely Ch., Silbernagel G., Vonbank A. , Mathies R., Drexel H. Baumgartner I. Systemic inflammation is higher in peripheral artery disease than in coronary artery disease *Atherosclerosis* 2015; 239: 299-303.
85. Brian Salmons; Eva Maria Brandtner; John A Dangerfield, Walter H Gunzburg: Encapsulation of Insulin Producing Cells for Diabetes Treatment Using Alginate and Cellulose Sulphate as Bioencapsulation Polymers. *Diabetes Research and Treatment* 2014; 1: 1-7.
86. Muendlein A, Kinz E Gasser K, Leiherer A, Rein P, Saely CH, Grallert H, Peters A, Fraunberger P, Drexel H, Lang AH. Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease. *Am J Hem* 2015; 90: E17-21.
87. Muendlein A, Leiherer A, Kinz E, Rein P, Vonbank A, Zanolin D, Malin C, Drexel H, Saely CH, Fraunberger P. Angiotensin-like protein 4 significantly predicts future cardiovascular events in coronary patients. *Atherosclerosis* 2014; 237: 632-638.
88. Leiherer A, Muendlein A, Rein P, Saely CH, Kinz E, Fraunberger P, Drexel H. Genome-wide association study reveals a polymorphism in the podocyte receptor RANK for the decline of renal function in coronary patients. *PLoS One* 2014; 9: e114240.
89. Biller K, Fae P, Germann R, Drexel H, Walli AK, Fraunberger P. Cholesterol rather than PCT or CRP predicts mortality in patients with infection Shock: Injury, Inflammation, and Sepsis 2014; 42: 129-132.
90. Chan K, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, Burnett S, Vaccarino VL, Zafari AM, Shah SH, Anderson JL, Carlquist JF, Hartiala J, Allayee H, Hinohara K, Lee BS, Erl A, Ellis KL, Goel A, Schaefer AS, El Mokhtari NE, Goldstein BA, Hlatky MA, Go AS, Shen GQ, Gong Y, Pepine C, Laxton RC, Whittaker JC, Tang WH, Johnson JA, Wang QK, Assimes TL, Nöthlings U, Farrall M, Watkins H, Richards AM, Cameron VA, Muendlein A, Drexel H, Koch W, Park JE, Kimura A, Shen WF, Simpson IA, Hazen SL, Horne BD, Hauser ER, Quyyumi AA,

- Reilly MP, Samani NJ, Ye S. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. *J Am Coll Cardiol* 2013; 957-
91. Puig L, Strohal R, Fuimann J, Pedersen R, Szumski A, Koenig AS, Robertson D, Drexel H. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. *J Dermatol Treatment* 2013; 25: 470-481.
 92. Muendlein A, Gasser K, Kinz E, Stark N, Leiherer A, Rein P, Saely CH, Grallert H, Peters A, Drexel H, Lang AH. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients. *Am J Hematol.* 2013; 89: 295-301.
 93. Höliner I, Haslinger V, Lutschg J, Müller G, Seick Barbarini D, Fussenegger J, Zanier U, Saely CH, Drexel H, Simma B. Validity of the Neurological Examination in Diagnosing Diabetic Peripheral Neuropathy. *Ped Neurol* 2013; 49:171-177.
 94. Vonbank A, Saely CH, Rein P, Sturn D, Drexel H. Current cholesterol guidelines and clinical reality: a comparison of two cohorts of coronary artery disease patients *Swiss Med Wkly* 2013; 143: w13827.
 95. Rein P, Saely CH, Vonbank A, Fraunberger P, Drexel H. Impact of the albumin to creatinine ratio and the coronary artery state on vascular events: Is Albuminuria a coronary artery disease equivalent? *Am J Cardiol* 2014; 113: 1616-1620.
 96. Saely CH, Drexel H. Is Type 2 Diabetes Really a Coronary Heart Disease Risk Equivalent? *Vasc Pharmacol* 2013; 59: 11-18.
 97. Vonbank A, Saely CH, Rein P, Drexel H. Insulin resistance is significantly associated with the metabolic syndrome, but not with sonographically proven peripheral arterial disease. *Cardiovasc. Diabetol* 2013; 12: 106.
 98. Rein P, Saely CH, Vonbank A, Boehnel C, Drexel. Serial Decline of kidney function predicts total mortality and cardiovascular events in coronary artery disease. *Am J Cardiol* 2014; 113: 215-221.
 99. Eber B, Lautsch D, Fauer C, Drexel H, Pfeiffer KP, Traindl , Pichler M. Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. *Curr Med Res Opin* 2012; 28: 1447-1454.
 100. Mann E, Vonbank A, Drexel H, Saely CH. Diabetes care among older adults in primary care in Austria: a cross-sectional study. *Swiss Med Wkly* 2012; 142: w13646.
 101. Zeppetzauer M, Drexel H, Vonbank A, Rein P, Aczel S, Saely CH. Eccentric endurance exercise economically improves metabolic and inflammatory risk factors. *Eur J Prev Cardiol* 2013; 20: 577-584.

102. Pichler M, Lautsch D, Adler C, Bögl K, Drexel H, Eber B, Fauer C, Föchterle J, Föger B, Gansch K, Grafinger P, Lechleitner M, Ludvik B, Maurer G, Mörz R, Paulweber B, Pfeiffer KP, Prager R, Stark G, Toplak H, Traindl O, Weitgasser R. Are there differences in LDL-C target value attainment in Austrian federal states? Yes! *Wien Med Wochenschr* 2013; 163: 528-535. PMID: 23979353
103. Saely CH, Rein P, Vonbank A, Huber K, Drexel H. Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events. *Int J Cardiol* 2013; 167: 776-780.
104. Lautsch D, Saely CH, Traindl O, Eber B, Pfeiffer KP, Drexel H. Is there a link between non-HDL cholesterol and blood pressure? An age and gender directed analysis of 7500 hypertensive outpatients. *J Kardiologie* 2012;19:11-16.
105. Othman A, Ruetli MF, Ernst D, Saely CH, Rein P, Drexel H, Porretta-Serapiglia, Lauria G, Bianchi R, von Eckardstein A, Hornemann T. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? *Diabetologia* 2012;55:421-431.
106. Muendlein A, Stark N, Rein P, Saely CH, Geller-Rhomberg S, Geiger K, Vonbank A, Drexel H. Are AHSN polymorphisms directly associated with coronary atherosclerosis? *Clin Chim Acta* 2012;413:287-290.
107. Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundmann P, da Silva PM, Pedersen T, Wood D, Juenger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal
108. Steiner C, Othman A, Saely CH, Rein P, Drexel H, von Eckardstein A, Rentsch KM. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. *PLoS One* 2011;6:e25006.
109. Drexel H, Chazelle F, Fauer C, Lautsch D, Gitt AK. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS). *Wien Klin Wochenschr* 2011;123:611-617.
110. Leiter LA, Lundman P, da Silva PM, Drexel H, Juenger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. *Diabet Med* 2011;28:1343-1351.
111. Muendlein A, Saely CH, Geller-Rhomberg S, Sonderegger G, Rein P, Winder T, Beer S, Vonbank A, Drexel H. Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. *PLoS One* 2011;6:e17978.
112. Rein P, Vonbank A, Saely CH, Beer S, Jankovic, V, Boehnel C, Breuss J, Risch L, Fraunberger P, Drexel H. Relation of albuminuria to angiographically determined coronary arterial

- narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease. *Am J Cardiol* 2011;107:1144-1148.
113. Vonbank A, Saely CH, Rein P, Beer S, Breuss J, Boehnel C, Drexel H. Insulin resistance is associated with the metabolic syndrome and is not directly linked to coronary artery disease. *Clin Chim Acta* 2011;412:1003-1007.
114. Saely CH, Vonbank A, Drexel H. HDL cholesterol and residual risk of first cardiovascular events. *Lancet* 2010;376:1738-1739.
115. Rein P, Saely CH, Beer S, Vonbank A, Drexel H. Roles of the metabolic syndrome, HDL cholesterol, and coronary atherosclerosis in subclinical inflammation. *Diabetes Care* 2010;33:1853-1855.
116. Sourij H, Saely CH, Schmid F, Zweiker R, Marte T, Wascher TC, Drexel H. Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographed coronary patients. *Eur Heart J* 2010;31:1583-1590.
117. Rein P, Saely CH, Muendlein A, Vonbank A, Drexel H. Serial decline of kidney function as a novel biomarker for the progression of atherothrombotic disease. *Atherosclerosis* 2010;211:348-352.
118. Saely CH, Aczel S, Koch L, Schmid F, Marte T, Huber K, Drexel H. Diabetes as a coronary artery disease risk equivalent: before a change of paradigm? *Eur J Cardiovasc Prev Rehabil* 2010;17:94-99.
119. Beer S, Saely CH, Hoefle G, Rein P, Vonbank A, Breuss J, Gaensbacher B, Muendlein A, Drexel H. Low bone mineral density is not associated with angiographically determined coronary atherosclerosis in men. *Osteoporos Int* 2010;21:1695-1701.
120. Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. *Atherosclerosis* 2010;208:484-489.
121. Saely CH, Eber B, Pfeiffer KP, Drexel H. Low serum LDL cholesterol in patients with type 2 diabetes: an analysis on two different patient populations. *Int J Cardiol* 2010;144:394-398.
122. Saely CH, Rein P, Vonbank A, Drexel H. Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective. *Int J Cardiol* 2010;144:448-449.
123. Rein P, Beer S, Saely CH, Vonbank A, Drexel H. Prevalence of impaired glucose metabolism in individuals with peripheral arterial disease. *Int J Cardiol* 2010;144:243-244.
124. Saely CH, Risch L, Frey F, Lupi GA, Leuppi JD, Drexel H, Huber AH. Body mass index, blood pressure, and serum cholesterol in young Swiss men: an analysis on 56784 army conscripts. *Swiss Med Wkly* 2009;139:518-524.

125. Muendlein A, Geller-Rhomberg S, Saely CH, Winder T, Sonderegger G, Rein P, Beer S, Vonbank A, Drexel H. Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis. *Atherosclerosis* 2009;206:494-499.
126. Muendlein A, Saely CH, Rhomberg S, Sonderegger G, Loacker S, Rein P, Beer S, Vonbank A, Winder T, Drexel H. Evaluation of the association of genetic variants on the chromosomal loci 9p21.3, 6q25.1, and 2q36.3 with angiographically characterized coronary artery disease. *Atherosclerosis* 2009;205:174-180.
127. Marte T, Saely CH, Schmid F, Koch L, Drexel H. Effectiveness of atrial fibrillation as an independent predictor of death and coronary events in patients having coronary angiography. *Am J Cardiol* 2009;103:36-40.
128. Rein P, Saely CH, Aczel S, Patsch B, Drexel H. Omega-3 fatty acids significantly reduce postprandial triglyceridemia in male smokers: a pilot study. *Nutr Metab Cardiovasc Dis* 2009;19:e3-e4.
129. Saely CH, Dyballa T, Vonbank A, Woess M, Rein P, Beer S, Jankovic V, Boehnel C, Aczel S, Drexel H. Type 2 diabetes but not coronary atherosclerosis is an independent determinant of impaired mobility in angiographed coronary patients. *Diabetes Res Clin Pract* 2008;82:185-189.
130. Saely CH, Vonbank A, Rein P, Woess M, Beer S, Aczel S, Jankovic V, Boehnel C, Risch L, Drexel H. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. *Clin Chim Acta* 2008;397:82-86.
131. Saely CH, Muendlein A, Vonbank A, Sonderegger G, Aczel S, Rein P, Risch L, Drexel H. Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1 -675 4G/5G polymorphism in angiographed coronary patients. *Clin Chim Acta* 2008;396:18-22.
132. Drexel H, Saely CH, Langer P, Loruenser G, Marte T, Risch L, Hoefle G, Aczel S. Metabolic and anti-inflammatory benefits of eccentric endurance exercise - a pilot study. *Eur J Clin Invest* 2008;38:218-226.
133. Muendlein A, Saely CH, Marte T, Schmid F, Koch L, Rein P, Langer P, Aczel S, Drexel H. Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease. *Atherosclerosis* 2008;199:179-186.
134. Saely CH, Drexel H, Sourij H, Aczel S, Jahnel H, Zweiker R, Langer P, Marte T, Hoefle G, Benzer W, Wascher TC. Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: an angiographic study. *Atherosclerosis* 2008;199:317-322.

135. Drexel H, Rein P, Hostalek U, Kastelein J. Clinical Experience with prolonged-release nicotinic acid in statin-treated patients managed in the usual care setting in Austria: An analysis from NiaspnR-induced HDL-elevation for optimizing risk control (NEMO) study. *J Clinical and Basic Cardiology* 2007;10:7-10.
136. Saely CH, Rein P, Drexel H. The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the International Diabetes Federation. *Horm Metab Res* 2007;39:642-650.
137. Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, Aczel S, Berchtold S, Drexel H. Relationship between the adipose-tissue hormone resistin and coronary artery disease. *Clin Chim Acta* 2007;386:1-6.
138. Hoefle G, Saely CH, Risch L, Rein P, Koch L, Schmid F, Aczel S, Marte T, Langer P, Drexel H. Leptin, leptin soluble receptor and coronary atherosclerosis. *Eur J Clin Invest* 2007;37:629-636.
139. Saely CH, Risch L, Hoefle G, Rein P, Muendlein A, Marte T, Aczel S, Langer P, Drexel H. Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis. *Clin Chim Acta* 2007;383:97-102.
140. Hoefle G, Muendlein A, Saely CH, Risch L, Rein P, Koch L, Schmid F, Aczel S, Marte T, Langer P, Drexel H. The -11377 C>G promoter variant of the adiponectin gene, prevalence of coronary atherosclerosis, and incidence of vascular events in men. *Thromb Haemost* 2007;97:451-457.
141. Risch L, Saely CH, Neyer U, Hoefle G, Gouya G, Zerlauth M, Risch GM, Risch M, Drexel H. Prevalence of decreased glomerular filtration rate in patients seeking non-nephrological medical care--an evaluation using IDMS-traceable creatinine based MDRD as well as Mayo Clinic quadratic equation estimates. *Clin Chim Acta* 2007;378:71-77.
142. Risch L, Saely C, Hoefle G, Rein P, Langer P, Gouya G, Marte T, Aczel S, Drexel H. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. *Clin Chim Acta* 2007;376:108-113.
143. Risch L, Hoefle G, Saely CH, Berchtold S, Drexel H. Evaluation of two fully automated novel enzyme-linked immunosorbent assays for the determination of human adiponectin in serum. *Clin Chim Acta* 2006;373:121-126.
144. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. *Diabetes Care* 2006;29:901-907.

145. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. *Eur J Clin Invest* 2006;36:91-97.
146. Risch L, Drexel H, Huber AR. Differences in glomerular filtration rate estimates by 2 cystatin C-based equations. *Clin Chem* 2005;51:2211-2212.
147. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. *J Clin Endocrinol Metab* 2005;90:5698-5703.
148. Hoefle G, Saely CH, Aczel S, Benzer W, Marte T, Langer P, Drexel H. Impact of total and central obesity on vascular mortality in patients undergoing coronary angiography. *Int J Obes (Lond)* 2005;29:785-791.
149. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? *Diabetes Care* 2005;28:101-107.
150. Risch L, Saely CH, Reist U, Hefti M, Reist K, Huber AR. Course of glomerular filtration rate markers in patients receiving high dose glucocorticoids following subarachnoidal hemorrhage. *Clin Chim Acta* 2005; 36:205-207.
151. Hofle G, Saely CH, Tautermann G, Aczel S, Holzmüller H, Drexel H. Relationship between various measures of bone mineral density and vertebral fractures in cardiac transplant recipients. *Swiss Med Wkly* 2004;134:215-220.
152. Hofle G, Tautermann G, Saely CH, Drexel H. Sex-hormone-binding globulin is negatively correlated with femoral bone-mineral density in male cardiac-transplant recipients. *Wien Klin Wochenschr* 2004;116:170-175.
153. Saely CH, Aczel S, Marte T, Langer P, Drexel H. Cardiovascular complications in Type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state. *Diabetologia* 2004;47:145-146.
154. Hofle G, Holzmüller H, Gouya G, Hergan K, Hubmann M, Langer P, Drexel H. Lower serum beta-CrossLaps in male cardiac transplant recipients treated without prednisolone. *Transpl Int* 2003;16:523-528.
155. Benzer W, Aczel S, Drexel H. A clinical practice model to estimate the cost. Effectiveness of lipid lowering therapy with statins in patients at risk for coronary artery disease. *J Clin Basic Cardiol* 2002;5:179-182.
156. Kuster GM, Amann FW, Neuenschwander C, Drexel H. High density-lipoprotein subfractions of patients using cardio-selective beta-blockers. *Cardiovasc Drugs Ther* 2002;16:127-131.
157. Geltner C, Lechleitner M, Foger B, Ritsch A, Drexel H, Patsch JR. Insulin improves fasting and postprandial lipemia in type 2 diabetes. *Eur J Intern Med* 2002;13:256-263.

158. Drexel H, Schmid HR, Follath F. Effects of bisoprolol on lipoprotein cholesterol subfractions and apolipoproteins in patients with hypertension. *J Clin Basic Cardiol* 2001;4:57.
159. Benzer W, Fritzsche H, Kargl M, Drexel H. Revascularization of residual viable myocardium improves left ventricular dysfunction in patients after myocardial infarction. *Wien Klin Wochenschr* 1999;111:636-642.
160. Fuchs W, Wolber T, Woss E, Neyer U, Drexel H. Leptospirosis (Weil's syndrome) with renal failure, severe jaundice, disseminated hemorrhages and xanthopsia. *Schweiz Med Wochenschr* 1999;129:847-850.
161. Drexel H, Gaul GB, Grimm G, Klein W, Kleemann L, Leisch F, Mlczech J, Pichler M, Sailer S, Slany J, Steinbach K, Tragl KH, Mori M, Kuhn P. Secondary prevention following coronary intervention. Survey of 13 intervention centers in Austria *Wien Klin Wochenschr* 1999;111:643-649.
162. Benzer W, Bitschnau R, Groechnig E, Aczel S, Drexel H. Regular physical activity and risk factors for coronary heart disease. *Circulation* 1998;98:2356.
163. Ritsch A, Drexel H, Amann FW, Pfeifhofer C, Patsch JR. Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. *Arterioscler Thromb Vasc Biol* 1997;17:3433-3441.

Original Papers, Oncology

164. Benda M, Reimann P, Bletzacher E, Muendlein A, Bernhard B, Hartmann B, Huynh M, Gasser K, Zojer N, Lang T, Göbel G, Bohn JP, Schmidt S, Gunsilius E, Nachbaur D, Jukic E, Locher M, Willenbacher E, Willenbacher W, Winder T, Steiner N. Real-World Data on the Efficacy of Daratumumab in Patients with elapsed/Refractory Multiple Myeloma and Amplification 1q. *Cancers (Basel)*. 2025 Apr 8;17(8):1261. doi: 10.3390/cancers17081261. PMID: 40282438; PMCID: PMC12025356.
165. Muendlein A, Heinzle C, Brandtner EM, Leiherer A, Geiger K, Gaenger S, Drexel H, Dechow T, Decker T. Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients. *Breast Cancer Res Treat*. 2023 Oct;201(3):571-576. doi: 10.1007/s10549-023-07045-4. Epub 2023 Jul 25. PMID: 37490173
166. Axel Muendlein, Christine Heinzle, Eva Maria Brandtner, Andreas Leiherer, Heinz Drexel, Tobias Dechow, Thomas Decker. Circulating glypican-4 is a predictor of 24-month overall survival in metastatic breast cancer. *ORT*, 2023;46(4):151-156.
167. Axel Muendlein, Kathrin Geiger, Christine Heinzle, Stella Gaenger, Thomas Winder, Luciano Severgnini, Patrick Reimann, Eva Maria Brandtner, Andreas Leiherer, Heinz Drexel, Thomas

- Decker, Christoph Nonnenbroich, Tobias Dechow. Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients. *J Cancer Res Clin Oncol*. 2023 Aug;149(9):6435-6444. doi: 10.1007/s00432-023-04623-3. Epub 2023 Feb 10. PMID:36763171.
168. Muendlein A, Severgnini L, Decker T, Heinzle C, Leiherer A, Geiger K, Drexel H, Winder T, Reimann P, Mayer F, Nonnenbroich C, Dechow T. Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients. *Front Oncol*. 2022 Oct 24;12:1045995. doi: 10.3389/fonc.2022.1045995. PMID: 36353562; PMCID: PMC9638102
 169. Decker T, Bichler M, Birtel A, Fischer G, Geiger K, Gaenger S, Nonnenbroich C, Dechow T, Muendlein A. Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors. *Oncol Res Treat*. 2022;45(5):248-253. doi: 10.1159/00052375 Epub 2022 Feb 25. PMID: 35220309
 170. Muendlein A, Geiger K, Gaenger S, Dechow T, Nonnenbroich C, Leiherer A, Drexel H, Gaumann A, Jagla W, Winder T, Mayer F, Decker T. Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. *Sci Rep*. 2021 Mar 24;11(1):6761. doi: 10.1038/s41598-021-86238-7. PMID: 33762647; PMCID: PMC7990915
 171. Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, Drexel H Hofmann W, Schindler V, Kapoor R, Decker T, Lang AH. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. *J Canc Res Clin Oncol* 2015; 141: 2005-2012.
 172. Kinz E, Leiherer A, Lang AH, Drexel H, Muendlein A. (2014) Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR. *Int J Lab Hematol* 2015; 37: 217-24.
 173. Muendlein M, Hubalek M, Geller-Rhomberg S, Gasser K, Winder T, Drexel H, Decker T, Müller-Holzner E, Chamson M, Marth C, Lang AH. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients *Eur J Canc* 2014; 50: 2134 - 2141.
 174. Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. *J Mol Diagn* 2011;13:23-28.
 175. Winder T, Schuster A, Becherer A et al. Advanced inoperable type B3 thymoma: monitoring of a novel therapeutic approach with radio-chemotherapy and sorafenib by FDG-PET and CT. *Nuklearmedizin* 2010;49:N41-N43.
 176. Winder T, Muendlein A, Gasser K, Lingg G, Walser J, Karner-Hanusch J, Dirschmid K, Drexel H, Lang A. Challenges and pitfalls in HNPCC: A pedigree of an austrian HNPCC family beyond four generations! *Mag Europ Med Oncol* 2009;2:41-44.

177. Winder T, Mundlein A, Rhomberg S, Dirschmid K, Hartmann B, Knauer M, Drexel H, Wenzl E, de Vries A, Lang A. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. *Oncol Rep* 2009;21:1283-1287.
178. Lang AH, Geller-Rhomberg S, Winder T, Stark N, Gasser K, Hartmann B, Kohler B, Grizelj I, Drexel H, Muendlein A. A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. *BMC Cancer* 2012;12:20.
179. Muendlein A, Lang AH, Geller-Rhomberg S, Winder T, Gasser K, Drexel H, Decker T, Mueller-Holzner E, Chamon M, Marth C, Hubalek M. Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. *J Cancer Res Clin Oncol* 2013; 139: 491-498.

Original Papers, Nephrology

180. Muendlein A, Brandtner EM, Schimpf J, Piribauer M, Geiger K, Heinzle C, Leiherer A, Drexel H, Freistätter O, Neyer U, Zitt E. Evaluation of Circulating Glypican-4 in Patients with ESKD. *Kidney360*. 2025 Mar 10;6(6):975-982. doi: 10.34067/KID.0000000744. PMID: 40063102; PMCID: PMC12233845.
181. Cesaroni G, Jaensch A, Renzi M, Marino C, Ferraro PM, Kerschbaum J, Haller P, Brozek W, Michelozzi P, Stafoggia M, de Hoogh K, Brunekreef B, Hoek G, Zitt E, Forastiere F, Nagel G, Weinmayr G. Association of air pollution with incidence of end-stage kidney disease in two large European cohorts. *Sci Total Environ*. 2024 Oct 20;948:174796. doi: 10.1016/j.scitotenv.2024.174796. Epub 2024 Jul 18. PMID: 39032743
182. Kadelbach P, Weinmayr G, Chen J, Jaensch A, Rodopoulou S, Strak M, de Hoogh K, Andersen ZJ, Bellander T, Brandt J, Cesaroni G, Fecht D, Forastiere F, Gulliver J, Hertel O, Hoffmann B, Hvidtfeldt UA, Katsouyanni K, Ketzel M, Leander K, Ljungman P, Magnusson PKE, Pershagen G, Rizzuto D, Samoli E, Severi G, Stafoggia M, Tjønneland A, Vermeulen R, Peters A, Wolf K, Raaschou-Nielsen O, Brunekreef B, Hoek G, Zitt E, Nagel G. Long-term exposure to air pollution and chronic kidney disease-associated mortality-Results from the pooled cohort of the European multicentre ELAPSE-study. *Environ Res*. 2024 Jul 1;252(Pt 3):118942. doi: 10.1016/j.envres.2024.118942. Epub 2024 Apr 20. PMID: 38649012
183. Fritz J, Brozek W, Concin H, Nagel G, Kerschbaum J, Lhotta K, Ulmer H, Zitt E. The Association of Excess Body Weight with Risk of ESKD Is Mediated Through Insulin Resistance, Hypertension, and Hyperuricemia. *J Am Soc Nephrol*. 2022 Jul;33(7):1377-1389. doi: 10.1681/ASN.2021091263. Epub 2022 May 2. PMID: 35500938; PMCID: PMC9257805
184. Davidovic T, Schimpf J, Abbassi-Nik A, Stockinger R, Sprenger-Mähr H, Lhotta K, Zitt E. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in

- Hemodialysis Patients. *Front Immunol.* 2022 Jun 23;13:907615. doi: 10.3389/fimmu.2022.907615. PMID: 35812459; PMCID: PMC9261096
185. Schimpf J, Davidovic T, Abbassi-Nik A, Sprenger-Mähr H, Lhotta K, Zitt E. Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients. *Transpl Int.* 2022 Mar 22;36:10357. doi: 10.3389/ti.2022.10357. PMID: 35391899; PMCID: PMC8980220
186. Schimpf J, Sprenger-Mähr H, Davidovic T, Lhotta K, Zitt E. Humoral Response in SARS-CoV-2 Convalescent Compared to Vaccinated Kidney Transplant Patients. *Transpl Int.* 2022 Jan 18;35:10060. doi: 10.3389/ti.2021.10060. PMID: 35185362; PMCID: PMC8842381
187. Dimai HP, Reichardt B, Zitt E, Concin H, Malle O, Fahrleitner-Pammer A, Svedbom A, Brozek W. Thirty years of hip fracture incidence in Austria: is the worst over? *Osteoporos Int.* 2022 Jan;33(1):97-104. doi: 10.1007/s00198-021-06086-z. Epub 2021 Aug 15. PMID: 34392387; PMCID: PMC8758599
188. Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, Benda MA, Sprenger-Mähr H, Winder T, Lhotta K. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. *Front Immunol.* 2021 Jun 16;12:704773. doi: 10.3389/fimmu.2021.704773. PMID: 34220867; PMCID: PMC8242233
189. Fritz J, Brozek W, Concin H, Nagel G, Kerschbaum J, Lhotta K, Ulmer H, Zitt E. The Triglyceride-Glucose Index and Obesity-Related Risk of End-Stage Kidney Disease in Austrian Adults. *JAMA Netw Open.* 2021 Mar 1;4(3):e212612. doi: 10.1001/jamanetworkopen.2021.2612. PMID: 33787913; PMCID: PMC8013829
190. Wolfram JM, Zitt E, Bach CM. Surgical Treatment for Severe Fixed Hyperkyphosis in an Adult Patient Suffering From Ankylosing Spondylitis and Hereditary Hypophosphatemia With Vertebral Osteopetrosis. *Clin Spine Surg.* 2020 Oct;33(8):307-313. doi: 10.1097/BSD.0000000000001011. PMID: 32453164
191. Zitt E, Fischer A, Lhotta K, Concin H, Nagel G. Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort. *Sci Rep.* 2020 May 5;10(1):7578. doi: 10.1038/s41598-020-64587-z. PMID: 32371883; PMCID: PMC7200724
192. Popp W, Knoll F, Sprenger-Mähr H, Zitt E, Lhotta K. Alprostadil treatment of critical limb ischemia in hemodialysis patients: A retrospective single-center analysis. *Wien Klin Wochenschr.* 2019 May;131(9-10):209-215.
193. Zitt E, Pscheidt C, Concin H, Kramar R, Peter RS, Beyersmann J, Lhotta K, Nagel G. Long-term risk for end-stage kidney disease and death in a large population-based cohort. *Sci Rep.* 2018 May 16;8(1):7729

194. Zitt E, Hafner-Giessauf H, Wimmer B, Herr A, Horn S, Friedl C, Sprenger-Mähr H, Kramar R, Rosenkranz AR, Lhotta K. Response to active hepatitis B vaccination and mortality in incident dialysis patients. *Vaccine*. 2017 Feb 1;35(5):814-820
195. Sprenger-Mähr H, Zitt E, Lhotta K. Acute Kidney Injury Treated with Dialysis outside the Intensive Care Unit: A Retrospective Observational Single-Center Study. *PLoS One*. 2016 Sep 27;11(9):e0163512 PubMed PMID: 27673681; PubMed Central PMCID: PMC5038962.
196. Zitt E, Pscheidt C, Concin H, Kramar R, Lhotta K, Nagel G. Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria. *PLoS One*. 2016 Aug 18;11(8):e0161376. PubMed PMID: 27537361; PubMed Central PMCID: PMC4990261.
197. Zitt E, Hafner-Giessauf H, Wimmer B, Herr A, Horn S, Friedl C, Sprenger-Mähr H, Kramar R, Rosenkranz AR, Lhotta K. Response to active hepatitis B vaccination and mortality in incident dialysis patients. *Vaccine*. 2017 Feb 1;35(5):814-820. PubMed PMID: 28049587.
198. Pronai W, Rosenkranz AR, Bock A, Klauser-Braun R, Jäger C, Pendl G, Hemetsberger M, Lhotta K. Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study. *Wien Klin Wochenschr*. 2017 PubMed PMID: 28091752.
199. Zitt E, Lhotta K. Management of secondary hyperparathyroidism-current impact of parathyroidectomy, *Wien Med Wochenschr* 2016 May;166(7-8):254-8. doi: 10.1007/s10354-016-0444-3
200. Raffler G, Zitt E, Sprenger-Mähr H, Nagel M, Lhotta K. Autosomal dominant tubulointerstitial kidney disease caused by uromodulin mutations: seek and you will find, *Wien Klin Wochenschrift* 2016 Apr;128(7-8):291-4. doi: 10.1007/s00508-015-0948-7
201. Pscheidt C, Nagel G, Zitt E, Kramar R, Concin H, Lhotta K. Sex- and Time-Dependent Patterns in Risk Factors of End-Stage Renal Disease: A Large Austrian Cohort with up to 20 Years of Follow-Up, *Plos one* 2015 Aug 31;10(8):e0135052. doi: 10.1371
202. Zitt E, Sprenger-Mähr H, Mündle M, Lhott K. Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency, *BMC Nephrology*, 2015 Aug 4;16(28), doi: 10.1186/s12882-015-0116-3
203. Ender M, Cejna M, Lhotta K. End-stage renal disease from renal metastases, *Kidney International* 2014, 87(246), doi:10.1038/ki.2014.140
204. Zitt E, Sturm G, Kroneneberg F, Neyer U, Knoll F, Lhotta K, Weiss G. Iron supplementation and mortality in incident dialysis patients: an observational study, *Plos One* 2014 Dec 2;9(12):e114144. doi: 10.1371/journal.pone.01141442014

205. Zitt E, Knoll F, Lhotta K. Variable mechanisms of vascular calcification in different segments of the arterial tree in patients with chronic kidney disease, *Kidney Int.* 2014 Oct;86(4):858. doi: 10.1038/ki.2014.183.
206. Jennings P, Crean D, Aschauer L, Limonciel A, Moenks K, Kern G, Hewitt P, Lhotta K, Lukas A, Wilmes A, Leonard MO. Interleukin-19 as a translational indicator of renal injury. *Arch Toxicol.* 2015 Jan;89(1):101-6. doi: 10.1007/s00204-014-1237-3
207. Kerschbaum J, Vychytil A, Lhotta K, Prischl F, Wiesholzer M, Machhold-Fabrizii V, Kopriva-Altfahrt G, Schwarz C, Balcke P, Oberbauer R, Kramar R, König P, Rudnicki M. Treatment with oral vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis, *PLoS One.* 2013 Jul 2;8(7):e67836. doi: 10.1371/journal.pone.0067836.
208. Risch L, Lhotta K, Meier D, Medina-Escobar P, Nydegger U, Risch M., The Serum uromodulin Level is associated with kidney function. *Clin Chem Lab Med.* 2014 Dec;52(12):1755-61. doi: 10.1515/cclm-2014-0505.
209. Nagel G, Zitt E, Peter R, Pompelle A, Concin H, Lhotta K. Body mass index and metabolic factors predict glomerular filtration rate and albuminuria over 20 years in a high-risk population, *BMC Nephrol.* 2013 Aug 20;14:177. doi: 10.1186/1471-2369-14-177
210. Moskowitz J, Piret S, Lhotta K, Kitzler T, Tashman A, Velez E, Thakker R, Kotanko P. Association between genotype and phenotype in uromodulin-associated kidney Disease, *Clin J Am Soc Nephrol.* 2013 Aug;8(8):1349-57. doi: 10.2215/CJN.11151012.
211. Meusburger E, Mündlein A, Zitt E, Obermayer-Pietsch B, Kotzot D, Lhotta K, Medullary nephrocalcinosis in an adult patient with idiopathic infantile hypercalcemia and a novel CYP24A1 mutation, *Clin Kidney J.* 2013 Apr;6(2):211-215., DOI: 10.1093/ckj/sft008
212. Zitt E, König M, Vychytil A, Auinger M, Wallner M, Gingenhel G, Schilcher G, Rudnicki M, Salmhofer H, Lhotta K., Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients, *Nephrol Dial Transplant.* 2013 May;28(5):1232-40. doi: 10.1093/ndt/gfs548.
213. Lhotta K. Bedeutung der Präodialysevorbereitung und Patienteninformation für die Wahl des Dialyseverfahrens, *Wien Med. Wochenschrift;* 2013 June; 163 (11);266-270; DOI 10.1007/s10354-013-0192-6, 2013
214. Knoll F, Zitt E, Intemann D, Lhotta K. Juvenile elastic arteries after 28 years of renal replacement therapy in a patient with complete complement C4 deficiency, *BMC Nephrology* 2012 Dec 2;13:161. doi: 10.1186/1471-2369-13-161
215. Lhotta K, Piret SE, Kramar R, Thakker RV, Sunder-Plassman G, Kotanko P. Epidemiology of uromodulin-associated kidney disease-results from a nation-wide survey, *Nephron Extra* 2012 Jan 2(1):147-58, doi: 10.1159/000339102

216. Zitt E, Sprenger-Mähr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease, *Vaccine*. 2012 Jan 20;30(5):931-5; doi: 10.1016/j.vaccine.2011.11.086
217. Zitt E, Lamina C, Sturm G, Knoll F, Lins F, Freistätter O, Kronenberg F, Lhotta K, Neyer U. Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients, *Clin J Am Soc Nephrol*. 2011 Nov;6(11):2650-6. doi: 10.2215/CJN.03780411.
218. Zitt E, Woess E, Mayer G, Lhotta K. Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism, *Transplantation*. 2011 Oct 27;92(8):883-9. doi: 10.1097/TP.0b013e31822d87e8.
219. Knoll F, Sturm G, Lamina C, Zitt E, Lins F, Freistätter O, Kronenberg F, Lhotta K, Neyer U. Coumarins and survival in incident dialysis patients. *Nephrol Dial Transplant*. 2012 Jan;27(1):332-7. doi: 10.1093/ndt/gfr341
220. Sturm G, Lamina C, Zitt E, Lhotta K, Haider F, Neyer U, Kronenberg F. Association of HbA1c values with mortality and cardiovascular events in diabetic dialysis patients. The INVOR study and review of the literature, *PLoS One*. 2011;6(5):e20093. doi: 0.1371/journal.pone.0020093.
221. Koch LD, Knoll F, Hartmann G, Lhotta K. Recurrent exit-site infection due to *Staphylococcus lugdunensis*--a virulent coagulase-negative *Staphylococcus*. *Perit Dial Int*. 2011 May-Jun;31(3):372-3. doi: 10.3747/pdi.2010.00272.
222. Gouya G, Sturm G, Lamina C, Zitt E, Freistätter O, Struck J, Wolzt M, Knoll F, Lins F, Lhotta K, Neyer U, Kronenberg F. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. *PLoS One*. 2011 Mar 7;6(3):e17803. doi: 10.1371/journal.pone.0017803.
223. Häring N, Mähr HS, Mündle M, Strohal R, Lhotta K. Early detection of renal damage caused by fumaric acid ester therapy by determination of urinary β 2-microglobulin. *Br J Dermatol*. 2011 Mar;164(3):648-51. doi: 10.1111/j.1365-2133.2010.10171.x.
224. Sturm G, Lamina C, Zitt E, Lhotta K, Lins F, Freistätter O, Neyer U, Kronenberg F. Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients. *Nephrol Dial Transplant*. 2010 Aug;25(8):2715-22. doi: 10.1093/ndt/gfq101
225. Lhotta K, Neuweiler J, Mark W, Wöss E. Sirolimus-associated acute interstitial nephritis in a renal allograft, *Transpl Int*. 2010 Jun;23(6):e22-3. doi: 10.1111/j.1432-2277.2009.01016.x.

Original Papers, *In Vitro* Studies

226. Geiger K, Muendlein A, Leiherer A, Gaenger S, Brandtner EM, Wabitsch M, Fraunberger P, Drexel H, Heinzle C. Myricetin attenuates hypoxia-induced inflammation in human adipocytes. *Mol Biol Rep*. 2023 Dec;50(12):9833-9843. doi: 10.1007/s11033-023-08865-9. Epub 2023 Oct 16. PMID: 37843712.
227. Ślęfarska-Wolak D, Heinzle C, Leiherer A, Ager C, Muendlein A, Mezmale L, Leja M, Corvalan AH, Drexel H, Królicka A, Shani G, Mayhew CA, Haick H, Mochalski P. Volatilomic Signatures of AGS and SNU-1 Gastric Cancer Cell Lines. *Molecules*. 2022 Jun 22;27(13):4012. doi: 10.3390/molecules27134012. PMID: 35807254; PMCID: PMC9268292
228. Leiherer A, Ślęfarska D, Leja M, Heinzle C, Mündlein A, Kikuste I, Mezmale L, Drexel H, Mayhew CA, Mochalski P. The Volatilomic Footprints of Human HGC-27 and CLS-145 Gastric Cancer Cell Lines. *Front Mol Biosci*. 2021 Jan 11;7:607904. doi: 10.3389/fmolb.2020.607904. PMID: 33585559; PMCID: PMC7874186
229. Mochalski P, Diem E, Unterkofler K, Mündlein A, Drexel H, Mayhew CA, Leiherer A. In vitro profiling of volatile organic compounds released by Simpson-Golabi-Behmel syndrome adipocytes. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2019 Jan 1;1104:256-261.
230. Leiherer A, Stoemmer K, Muendlein A, Saely CH, Kinz E, Brandtner EM, Fraunberger P, Drexel H. Quercetin impacts expression of metabolism - and obesity-associated genes in SGBS adipocytes. *Nutrients* 2016; 8: E282.
231. Leiherer A, Geiger K, Muendlein A, Drexel H. Hypoxia induces a HIF-1 α dependent signaling cascade to make a complex metabolic switch in SGBS-adipocytes. *Mol Cell Endocrinol*. 2013; 383: 21-31.
232. Geiger K, Leiherer A, Muendlein A, Stark N, Geller-Rhomberg S, Saely CH, Wabitsch M, Fraunberger P, Drexel H. Identification of hypoxia-induced genes in human SGBS adipocytes by microarray analysis. *PLoS One* 2011;6:e26465.
233. Geiger K, Muendlein A, Stark N, Saely CH, Wabitsch M, Fraunberger P, Drexel H. Hypoxia induces apelin expression in human adipocytes. *Horm Metab Res* 2011;43:380-385.

Original Papers, Other Research Areas

234. Mink S, Drexel H, Leiherer A, Cadamuro J, Hitzl W, Frick M, Reimann P, Saely CH, Fraunberger P. Interplay of statin treatment and anti-SARS-CoV-2 antibody levels in the outcome of COVID-19: a prospective, propensity score matched cohort study. *Atherosclerosis*. 2025 Sep;408:120449. doi: 10.1016/j.atherosclerosis.2025.120449. Epub 2025 Jul 19. PMID: 40712415.

235. Mink S, Drexel H, Leiherer A, Cadamuro J, Hitzl W, Zitt E, Frick M, Reimann P, Saely CH, Fraunberger P. Interplay of kidney function and anti-SARS-CoV-2 antibodies in COVID-19 mortality: a prospective cohort study. *Sci Rep.* 2025 Jul 10;15(1):24978. doi: 10.1038/s41598-025-98788-1. PMID: 40640492; PMCID: PMC12246416
236. Fritz J, Jochems SHJ, Bjørge T, Wood AM, Häggström C, Ulmer H, Nagel G, Zitt E, Engeland A, Harlid S, Drake I, Stattin P, Stocks T Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. *Br J Cancer.* 2024 Feb;130(2):308-316. doi: 10.1038/s41416-023-02526-1. Epub 2023 Dec 12. PMID: 38087039
237. Mink S, Saely CH, Leiherer A, Reimann P, Frick M, Cadamuro J, Hitzl W, Drexel H, Fraunberger P. Antibody levels versus vaccination status in the outcome of older adults with COVID-19. *JCI Insight.* 2024 Oct 22;9(20):e183913. doi: 10.1172/jci.insight.183913. PMID: 39435658; PMCID: PMC11529978.
238. Mink S, Drexel H, Leiherer A, Cadamuro J, Hitzl W, Frick M, Reimann P, Saely CH, Fraunberger P. Anti-SARS-CoV-2 Antibodies versus Vaccination Status in CAD Patients with COVID-19: A Prospective, Propensity Score-Matched Cohort Study. *Vaccines (Basel).* 2024 Jul 30;12(8):855. doi: 10.3390/vaccines12080855. PMID: 39203980; PMCID: PMC11359237.
239. Reimann P, Petzer V, Mündlein A, Hartmann B, Severgnini L, Winkler A, Lang T, Huynh M, Gasser K, Rüger J, Atzl M, Mink S, Fraunberger P, Schmidt S, Steiner N, Griesmacher A, Gunsilius E, Nachbaur D, Willenbacher W, Wolf D, Winder T, Benda MA. Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies. *Ann Hematol.* 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2. PMID: 38436671.
240. Mink S, Drexel H, Leiherer A, Frick M, Reimann P, Saely CH, Fraunberger P. Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study. *Int J Infect Dis.* 2024 Jun;143:107016. doi: 10.1016/j.ijid.2024.107016.
241. Brozek W, Clemens P, Ulmer H, Häring N, Concin H, Zitt E, Nagel G. Evaluation of a Population-Based Targeted Screening Approach for Skin Cancer with Long-Time Follow-Up in Austria including Potential Effects on Melanoma Mortality. *Cancers (Basel).* 2024 Mar 26;16(7):1283. doi: 10.3390/cancers16071283.
242. Mareth C, Fetzner UK, Saely CH. Age and professional experience as determinants of the utilization of psychoneuroimmunological research in clinical practice: An exploratory study. *Medicine (Baltimore).* 2023 Aug 5;102(34):e34723. doi: 10.1097/MD.00000000000034723. PMID: 37653748; PMCID: PMC10470779
243. Mink S, Saely CH, Leiherer A, Frick M, Plattner T, Drexel H, Fraunberger P. Anti-SARS-CoV-2 antibody levels predict outcome in COVID-19 patients with type 2 diabetes: a prospective

- cohort study. *Sci Rep.* 2023 Oct 26;13(1):18326. doi: 10.1038/s41598-023-45700-4. PMID: 37884649; PMCID: PMC10603091.
244. Mink S, Saely CH, Frick M, Leiherer A, Drexel H, Fraunberger P. Association between Lipid Levels, Anti-SARS-CoV-2 Spike Antibodies and COVID-19 Mortality: A Prospective Cohort Study. *J Clin Med.* 2023 Aug 1;12(15):5068. doi: 10.3390/jcm12155068. PMID: 37568470; PMCID: PMC10420155.
245. Sun M, Fritz J, Häggström C, Bjørge T, Nagel G, Manjer J, Engeland A, Zitt E, van Guelpen B, Stattin P, Ulmer H, Stocks T. Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study. *J Natl Cancer Inst.* 2023 Apr 11;115(4):456-467. doi: 10.1093/jnci/djad008. PMID: 36647199; PMCID: PMC10086630
246. Mink S, List W, Hoefle G, Frick M, Suessenbacher A, Winder T, Fetz C, Boesl A, Saely CH, Drexel H, Fraunberger P. Evaluation of SARS-CoV-2 antibody levels on hospital admission as a correlate of protection against mortality. *J Intern Med.* 2023 Jan 22. doi: 10.1111/joim.13606. Epub ahead of print. PMID: 36682036.
247. Brozek W, Ulmer H, Pompella A, Nagel G, Leiherer A, Preyer O, Concin H, Zitt E. Response to comments on "Gamma-glutamyl-transferase is associated with incident hip fractures in women and men $\geq$ 50 years: a large population-based cohort study". *Osteoporos Int.* 2022 Aug;33(8):1827-1829. doi: 10.1007/s00198-022-06442-7. Epub 2022 Jun 28. PMID: 35763075
248. Brozek W, Ulmer H, Pompella A, Nagel G, Leiherer A, Preyer O, Concin H, Zitt E. Gamma-glutamyl-transferase is associated with incident hip fractures in women and men $\geq$ 50 years: a large population-based cohort study. *Osteoporos Int.* 2022 Jun;33(6):1295-1307. doi: 10.1007/s00198-022-06307-z. Epub 2022 Jan PMID: 35059776
249. Hoffmann C, Wechselberger T, Drexel H, Dertinger S, Dirnhofer S, Pierson SK, Fajgenbaum DC, Kessler A. Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine. *Vaccines (Basel).* 2022 Oct 15;10(10):1725. doi: 10.3390/vaccines10101725. PMID: 36298590; PMCID: PMC9609308
250. Atzl M, Muendlein A, Winder T, Fraunberger P, Brandtner EM, Geiger K, Klausberger M, Duerkop M, Sprenger L, Mutschlechner B, Volgger A, Benda M, Severgnini L, Jaeger JB, Drexel H, Lang A, Leiherer A. SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study. *BMJ Open.* 2022 May 24;12(5):e052130. doi: 10.1136/bmjopen-2021-052130. PMID: 35613821; PMCID: PMC9174531
251. Geiger K, Zach C, Leiherer A, Fraunberger P, Drexel H, Muendlein A. Real- time PCR based HLA-B*27 screening directly in whole blood. *HLA.* 2020 Mar;95(3):189-195. doi: 10.1111/tan.13767. Epub 2019 Dec 1. PMID: 31749313

252. Geiger K, Zach C, Leiherer A, Fraunberger P, Drexel H, Muendlein A. Real-time PCR based HLA-B*27 screening directly in whole blood. *HLA*. 2020 Mar;95(3):189-195
253. Zach C, Unterkofler K, Fraunberger P, Drexel H, Muendlein A. Unrecognized High Occurrence of Genetically Confirmed Hereditary Carnitine Palmitoyltransferase II Deficiency in an Austrian Family Points to the Ongoing Underdiagnosis of the Disease. *Front Genet*. 2019 May 22;10:497
254. Muendlein A, Leiherer A, Zach C, Brandtner EM, Fraunberger P, Drexel H, Geiger K. Real-time PCR based detection of the lactase non-persistence associated genetic variant LCT-13910C>T directly from whole blood. *Mol Biol Rep*. 2019 Apr;46(2):2379-2385
255. Geiger K, Leiherer A, Brandtner EM, Fraunberger P, Drexel H, Muendlein A. Direct blood PCR: TaqMan-probe based detection of the venous thromboembolism associated mutations factor V Leiden and prothrombin c.20210G>A without DNA extraction. *Clin Chim Acta*. 2019 Jan;488:221-225
256. Walter-Höliner I, Barbarini DS, Lutschg J, Blassnig-Ezeh A, Zanier U, Saely CH, Simma B. High Prevalence and Incidence of Diabetic Peripheral Neuropathy in Children and Adolescents With Type 1 Diabetes Mellitus: Results From a Five-Year Prospective Cohort Study. *Pediatr Neurol*. 2018 Mar;80:51-60
257. Kinz E, Muendlein A. Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System. *Methods Mol Biol*. 2018;1768:257-273
258. Huegel R, Muendlein A, Volbeding L, Drexel H, Richtig E, Wehkamp U, Painsi C, Lange-Asschenfeldt B, Hausschild A, Egberts F. Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. *Melanoma Res*. 2016 Aug;26(4):354-60
259. Biebl A, Muendlein A, Kinz E, Drexel H, Kabesch M, Zenz W, Elling R, Müller C, Keil T, Lau S, Simma B. Confirmation of Host Genetic Determinants in the CFH Region and Susceptibility to Meningococcal Disease in a Central-European Study Sample. *Pediatr Infect Dis J*. 2015; 34: 1115-1117.
260. DeVries AF, Piringer G, Kremser C, Judmaier W, Saely CH, Lukas P, Ofner D. Pretreatment evaluation of microcirculation by dynamic contrast-enhanced magnetic resonance imaging predicts survival in primary rectal cancer patients. *Int J Radiat Oncol Biol Phys* 2014; 90: 1161-1167.
261. Biebl A, Muendlein A, Kazakbaeva Z, Heuberger S, Sonderegger G, Drexel H, Lau S, Nickel R, Kabesch M, Simma B. CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patients. *PLoS One* 2009;4:e7374.
262. Rhomberg W, Eiter H, Schmid F, Sealy CH. Combined Vindesine and Razoxane Shows Antimetastatic Activity in Advanced Soft Tissue Sarcomas. *Clin Exp Metastasis* 2008; 75-80.

263. Rhomberg W, Eiter H, Schmid F, Saely CH. Razoxane and Vindesine in Advanced Soft Tissue Sarcomas: Impact on Metastasis, Survival and Radiation Response. *Anticancer Res* 2007; 27: 3609-3614.
264. Zuber-Jerger I, Drexel H. Aphthous colitis induced by non-steroidal antirheumatic drugs. *Swiss Med Wkly* 2003;133:544-545.
265. Wiederin TBJ, Krings T, Vonbank H, Hergan K, Peschina W, Fritsche H, Mathies R, Drexel H, Koppi S. MRI, proton magnetic resonance spectroscopy and Tc-99m HMPAO SPECT in a patient with transient global amnesia. *Neuroradiol* 2001;11:216-220.
266. Tautermann G, Ruebsamen H, Beck M, Dertinger S, Drexel H, Lohse P. R116C mutation of cationic trypsinogen in a Turkish family with recurrent pancreatitis illustrates genetic microheterogeneity of hereditary pancreatitis. *Digestion* 2001;64:226-232.
267. Dertinger S, Dirschmid K, Vogel W, Drexel H. Immunosuppressive therapy for carbamazepine-induced hypersensitivity syndrome and hepatitis. *J Hepatol* 1998;28:356-357.

Case Reports

268. Zhang S, Muendlein A, Meusburger E, Zitt E. Persistent Hypercalcemia Despite Parathyroidectomy for Primary Hyperparathyroidism in an Adult with Nephrocalcinosis and Nephrolithiasis Caused by a Novel Combination of Two Pathogenic CYP24A1 Mutations. *Int J Mol Sci*. 2025 Sep 15;26(18):8965. doi: 10.3390/ijms26188965. PMID: 41009532; PMCID: PMC12469753.
269. Schimpf J, Haller P, Zitt E. Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report. *Front Immunol*. 2025 Apr 28;16:1588471. doi: 10.3389/fimmu.2025.1588471. PMID: 40356910; PMCID: PMC12066623.
270. Kinz W, Schnetzer L, Fraunberger P, Drexel H. Fast Decline of Low-Density Lipoprotein Cholesterol after a First Dose of Inclisiran: A Case Report. *J Cardiol Cardiovasc Ther* 2024; 19: DOI: 10.19080/JOCCT.2024.19.556013
271. Rosenov A, Schindewolf M, Baumgartner I, Saely C. Selective Arterial Embolizations of Renal Angiomyolipomas Using 96% Ethanol: A Case Series of 5 Patients. *Clin Med Insights Case Rep*. 2020 Feb 17;13:1179547620906863. doi: 10.1177/1179547620906863. PMID: 32110130; PMCID: PMC7026809
272. Lhotta K, Zitt E. An unusual case of acute kidney injury after colonoscopy. *Kidney Int*. 2017 Apr;91(4):989

273. Sprenger-Mähr H, Zitt E, Lhotta K. Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis, *Case Rep Transplant* 2016;2016:7137584. doi: 10.1155/2016/7137584
274. Stanic M, Meusburger E, Hartmann G, Lhotta K. *Hafnia alvei* urosepsis in a kidney transplant patient *Case Rep Transplant* 2015 April, doi.org/10.1155/2015/863131
275. Valentiny C, Dierschmid H, Lhotta K. *Streptococcus uberis* and *staphylococcus aureus* forefoot and blood stream co-infection in a hemodialysis patient: a case report, *BMC Nephrology*, 2015 May 28;16(73), doi: 10.1186/s12882-015-0069-6
276. Kronbichler A, Frank R, Kirschfink M, Szilagy A, Csuka D, Prohaszka Z, Schratzberger P, Lhotta K. Efficacy of eculizumab in a patient with immunoabsorption-dependent catastrophic antiphospholipid syndrome: a case report, *Medicine* 2014, 93(26):e143., doi: 10.1097/MD.0000000000000143.
277. Gouya G, Hartmann G, Fae P, Teuber M, Holzmueller H, Benzer W, Lang A, Schuster A, Drexel H. A case of fulminant post-transplant lymphoproliferative disorder and septicemia. *Clin Transplant* 2006;20:261-264.

Reviews

278. Luedde M, Agewall S, Ambrosio G, Bayes-Genis A, Borghi C, Cerbai E, Dan GA, Drexel H, Ferdinandy P, Grove EL, Kaski JC, Klingenberg R, Morais J, Parker W, Petrie MC, Rocca B, Semb AG, Senni M, Sohns C, Sulzgruber P, Tamargo J, Metra M, Böhm M, Dobrev D, Sossalla S. European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action. *Eur J Heart Fail.* 2025 Oct 22. doi: 10.1002/ejhf.70069. Epub ahead of print. PMID: 41123042.
279. Drexel H, Festa A, Schmidt TA, Rocca B, Dobrev D, Agewall S, Tamargo J, Kaser S. Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus. *Eur Heart J Cardiovasc Pharmacother.* 2025 Oct 27:pva076. doi: 10.1093/ehjcvp/pva076. Epub ahead of print. PMID: 41143728
280. Klingenberg R, Leihner A, Dobrev D, Kaski JC, Levkau B, März W, Sossalla S, von Eckardstein A, Drexel H. Ceramides in cardiovascular disease: emerging role as independent risk predictors and novel therapeutic targets. *Cardiovasc Res.* 2025 Aug 14;121(9):1345-1358. doi: 10.1093/cvr/cvaf093. PMID: 40460239; PMCID: PMC12352314.
281. Kaser S, Dobrev D, Rocca B, Kaski JC, Agewall S, Drexel H. Management of dyslipidaemia in patients with comorbidities-facing the challenge: type 1 diabetes mellitus. *Eur Heart J*

- Cardiovasc Pharmacother. 2025 Jul 7;11(4):380-386. doi: 10.1093/ehjcvp/pvaf023. PMID: 40396997; PMCID: PMC12231131.
282. Tamargo J, Agewall S, Ambrosio G, Borghi C, Cerbai E, Dan GA, Drexel H, Ferdinandy P, Grove EL, Klingenberg R, Morais J, Parker W, Rocca B, Sulzgruber P, Semb AG, Sossalla S, Kaski JC, Dobrev D. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024. *Eur Heart J Cardiovasc Pharmacother*. 2025 May 2;11(3):292-317. doi: 10.1093/ehjcvp/pvaf012.
283. Muendlein A, Leiherer A, Drexel H. Evaluation of circulating glypican 4 as a novel biomarker in disease - A comprehensive review. *J Mol Med (Berl)*. 2025 Apr;103(4):355-364. doi: 10.1007/s00109-025-02520-5. Epub 2025 Feb 17. PMID: 39961831.
284. Frühwald L, Fasching P, Dobrev D, Kaski JC, Borghi C, Wassmann S, Huber K, Semb AG, Agewall S, Drexel H. Management of dyslipidaemia in patients with comorbidities-facing the challenge. *Eur Heart J Cardiovasc Pharmacother*. 2025 Mar 13;11(2):164-173. doi: 10.1093/ehjcvp/pvae095. PMID: 39719399; PMCID: PMC12063584
285. Mayer G, Dobrev D, Kaski JC, Semb AG, Huber K, Zirlik A, Agewall S, Drexel H. Management of dyslipidaemia in patients with comorbidities: facing the challenge. *Eur Heart J Cardiovasc Pharmacother*. 2024 Nov 6;10(7):608-613. doi: 10.1093/ehjcvp/pvae058. PMID: 39153964
286. Sayour NV, Paál ÁM, Ameri P, Meijers WC, Minotti G, Andreadou I, Lombardo A, Camilli M, Drexel H, Grove EL, Dan GA, Ivanescu A, Semb AG, Savarese G, Dobrev D, Crea F, Kaski JC, de Boer RA, Ferdinandy P, Varga ZV. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence. *Eur Heart J*. 2024 Apr 7;45(14):1224-1240. doi: 10.1093/eurheartj/ehae105. PMID: 38441940; PMCID: PMC11023004.
287. Drexel H, Mader A. Bempedoic acid - how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use. *Cardiology*. 2023 Nov 21. doi: 10.1159/000535372. Epub ahead of print. PMID: 37989119
288. Telser J, Grossmann K, Wohlgend N, Risch L, Saely CH, Werner P. Phosphorylated tau in Alzheimer's disease. *Adv Clin Chem*. 2023;116:31-111. doi: 10.1016/bs.acc.2023.05.001. Epub 2023 Jun 9. PMID: 37852722.
289. Drexel H, Tamargo J, Kaski JC, Lewis BS, Saely CH, Fraunberger P, Dobrev D, Komiyama M, Plattner T, Agewall S, Hasegawa K. Triglycerides Revisited: is Hypertriglyceridaemia a Necessary Therapeutic Target in Cardiovascular Disease? *Eur Heart J Cardiovasc Pharmacother*. 2023 Jun 16;pvad044. doi: 10.1093/ehjcvp/pvad044. Epub ahead of print. PMID: 37328424.
290. Klement M, Drexel H, Saely CH. Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review. *Inflammopharmacology*. 2023 Aug;31(4):1647-1656. doi: 10.1007/s10787-023-01209-w. Epub 2023 Jun 1. PMID: 37261626.

291. Drexel H, Saely CH, Agewall S. Fibrates: One more lost paradise in lipid treatment. *Eur Heart J Cardiovasc Pharmacother*. 2023 Jan 4;pvac072. doi: 10.1093/ehjcvp/pvac072. Epub ahead of print. PMID: 36610735
292. Tamargo J, Kaski JC, Kimura T, Barton JC, Yamamoto K, Komiyama M, Drexel H, Lewis BS, Agewall S, Hasegawa K. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events. *Eur Heart J Cardiovasc Pharmacother*. 2022 Sep 29;8(7):738-751. doi: 10.1093/ehjcvp/pvac040. PMID: 35848895; PMCID: PMC9520447
293. Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferović PM, Wanner C. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. *Cardiovasc Diabetol*. 2022 Aug 4;21(1):144. doi: 10.1186/s12933-022-01575-9. PMID: 35927730; PMCID: PMC9351217
294. Tamargo J, Kjeldsen KP, Delpón E, Semb AG, Cerbai E, Dobrev D, Savarese G, Sulzgruber P, Rosano G, Borghi C, Wassman S, Torp-Pedersen CT, Agewall S, Drexel H, Baumgartner I, Lewis B, Ceconi C, Kaski JC, Niessner A. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J Cardiovasc Pharmacother*. 2022 Jun 8;8(4):406-419. doi: 10.1093/ehjcvp/pvac005. PMID: 35092425
295. Telser J, Risch L, Saely CH, Grossmann K, Werner P. P-tau217 in Alzheimer's disease. *Clin Chim Acta*. 2022 Jun 1;531:100-111. doi: 10.1016/j.cca.2022.03.018. Epub 2022 Mar 24. PMID: 35341762
296. Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, Agewall S. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. *Eur Heart J Cardiovasc Pharmacother*. 2022 May 5;8(3):302-310. doi: 10.1093/ehjcvp/pvab048. PMID: 34180504
297. Groß RW, Schmieder E, Fetzner UK, Kleinert R, Nisi A, Saely C. Beeinflusst das orale Mikrobiom kanzerogene Veränderungen des Ösophagus? [Does the Oral Microbiome Influence Carcinogenic Changes of the Esophagus? - A Systematic Review]. *Ther Umsch*. 2022 Apr;79(3-4):159-166. German. doi: 10.1024/0040-5930/a001343. PMID: 35440197
298. Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. *Eur Heart J Cardiovasc Pharmacother*. 2020 Apr 1;6(2):97-103. doi: 10.1093/ehjcvp/pvz029. PMID: 31298686
299. Schillemans T, Tragante V, Maitusong B, Gigante B, Cresci S, Laguzzi F, Vikström M, Richards M, Pilbrow A, Cameron V, Foco L, Doughty RN, Kuukasjärvi P, Allayee H, Hartiala JA, Tang

- WHW, Lyytikäinen LP, Nikus K, Laurikka JO, Srinivasan S, Mordi IR, Trompet S, Kraaijeveld A, van Setten J, Gijssberts CM, Maitland-van der Zee AH, Saely CH, Gong Y, Johnson JA, Cooper-DeHoff RM, Pepine CJ, Casu G, Leiherer A, Drexel H, Horne BD, van der Laan SW, Marziliano N, Hazen SL, Sinisalo J, Kähönen M, Lehtimäki T, Lang CC, Burkhardt R, Scholz M, Jukema JW, Eriksson N, Åkerblom A, James S, Held C, Hagström E, Spertus JA, Algra A, de Faire U, Åkesson A, Asselbergs FW, Patel RS, Leander K. Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual- Level Meta-Analysis. *Front Physiol.* 2022 Jun 23;13:909870. doi: 10.3389/fphys.2022.909870. PMID: 35812313; PMCID: PMC9260705
300. Krogager ML, Kragholm K, Thomassen JQ, Sjøgaard P, Lewis BS, Wassmann S, Baumgartner I, Ceconi C, Schmidt TA, Kaski JC, Drexel H, Semb AG, Agewall S, Niessner A, Savarese G, Kjeldsen KP, Borghi C, Tamargo J, Torp-Pedersen C. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J Cardiovasc Pharmacother.* 2021 Nov 3;7(6):557-567. doi: 10.1093/ehjcvp/pvab038. PMID: 33956964
301. Savarese G, Reiner MF, Uijl A, D'Amario D, Agewall S, Atar D, Baumgartner I, Borghi C, De Carlo M, Drexel H, Kaski JC, Kjeldsen KP, Kucher N, Lund LH, Niessner A, Semb AG, Schmidt TA, Sulzgruber P, Tamargo J, Vitale C, Wassmann S, Aboyans V, Lewis BS. Antithrombotic Therapy and Major Adverse Limb Events in Patients With Chronic Lower Extremity Arterial Disease: Systematic Review and Meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases. *Eur Heart J Cardiovasc Pharmacother.* 2019 Aug 8
302. Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S. The age of RCT's 3 Important Aspects of RCT's in Cardiovascular Pharmacotherapy with examples from Lipid and Diabetes Trials. *Eur Heart J Cardiovasc Pharmacother.* 2019 Jul 12. pii: pvz029
303. Schernthaner G, Drexel H, Moshkovich E, Zilaitiene B, Martinka E, Czupryniak L, Várkonyi T, Janež A, Ducena K, Lalić K, Tankova T, Prázný M, Smirčić Duvnjak L, Sukhareva O, Sourij H. SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class. *BMC Endocr Disord.* 2019 Jun 17;19(1):64
304. Huber J, Smeikal M, Saely CH, Stingl H, Lechleitner M, Fasching P. [Geriatric aspects for the management of diabetes mellitus (Update 2019)]. *Wien Klein Wochenschr.* 2019 May;131(Suppl 1):236-245. doi: 10.1007/s00508-019-1463-z. Review. German

305. Wascher TC, Paulweber B, Toplak H, Saely CH, Drexel H, Föger B, Hoppichler F, Stulnig T, Stingl H, Clodi M; den Ausschuss Leitlinien. [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2019)]. *Wien Klin Wochenschr.* 2019 May;131(Suppl 1):136-138. doi: 10.1007/s00508-019-1444-2. Review. German.
306. Wascher TC, Saely CH; den Ausschuss Leitlinien. [Inhibition of platelet aggregation (Update 2019)]. *Wien Klin Wochenschr.* 2019 May;131(Suppl 1):139-140. doi: 10.1007/s00508-018-1437-6. Review. German.
307. Clodi M, Saely CH, Hoppichler F, Resl M, Steinwender C, Stingl H, Wascher TC, Winhofer-Stöckl Y, Sourij H. [Diabetes mellitus, coronary artery disease und heart disease (Update 2019)]. *Wien Klin Wochenschr.* 2019 May;131(Suppl 1):169-173. doi: 10.1007/s00508-019-1488-3. Review. German
308. Lechleitner M, Clodi M, Abrahamian H, Brath H, Brix J, Drexel H, Fasching P, Föger B, Francesconi C, Fröhlich-Reiterer E, Harreiter J, Hofer SE, Hoppichler F, Huber J, Kaser S, Kautzky-Willer A, Ludvik B, Luger A, Mader JK, Paulweber B, Pieber T, Prager R, Rami-Merhar B, Resl M, Riedl M, Roden M, Saely CH, Schelkshorn C, Schernthaner G, Sourij H, Stechemesser L, Stingl H, Toplak H, Wascher TC, Weitgasser R, Winhofer-Stöckl Y, Zlamal-Fortunat S. [Insulin therapy of type 2 diabetes mellitus (Update 2019)]. *Wien Klin Wochenschr.* 2019 May;131(Suppl 1):39-46. doi: 10.1007/s00508-019-1492-7. Review. German
309. Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, Savarese G, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, Tamargo J. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. *Eur Heart J Cardiovasc Pharmacother.* 2018 Oct 1;4(4):230-236. doi: 10.1093/ehjcvp/pvy028. Review. Erratum in: *Eur Heart J Cardiovasc Pharmacother.* 2019 Jan 1;5(1):36. *Eur Heart J Cardiovasc Pharmacother.* 2019 Jan 1;5(1):36. PubMed PMID: 30099530.
310. Schernthaner G, Khunti K, Lotan C, Burnier M, Drexel H, Prázný M. Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). *Ther Clin Risk Manag.* 2017 Dec 13;13:1569-1576. doi: 10.2147/TCRM.S144362
311. Granitzer E, Meier B, Drexel H, Saely CH Auswirkungen von Flohsamen (Psyllium) auf Parameter des Glukosestoffwechsels: Eine Übersicht. *Complement Med Res.* 2017;24(3):164-171
312. Tamargo J, Rosano G, Thomas W, Duarte J, Niessner A, Kaski JC, Cecconi C, Drexel H, Kjeldsen K, Savarese G, Torp-Pedersen C, Atar D, Lewis BS, Agewall S. Gender differences in the effects of cardiovascular drugs. *Eur Heart J Cardiovasc Pharmacother.* 2017

- 313. Saely CH, Drexel H. Impact of diet and exercise on proprotein convertase subtilisin/kexin 9: A mini-review. *Vascul Pharmacol.* 2016 Dec;87:10-13. PMID: 27746375
- 314. Leiherer A, Muendlein A, Drexel H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. *Vascul Pharmacol* 2013; 58:3-20
- 315. Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review. *Gerontology* 2012;58:15-23
- 316. Saely CH, Drexel H, Huber K. High-dose statin therapy for high-risk patients. *Herz* 2010;35:497-502. PMID: 20941469
- 317. Fraunberger P, Drexel H, Walli AK. Pathophysiology of sepsis and possible influence of statins. *Dtsch Med Wochenschr* 2010;135:2128-2132. PMID: 20960384
- 318. Winder, T, Lang, A, und Mündlein A (2011) Molekulare Diagnostik am Beispiel des kolorektalen Karzinoms, *Tumordiagnostik und Therapie* 32: 66-69
- 319. Muendlein A, Winder T, Loacker S, Drexel H. Einfluss von DNA-Variationen auf die koronare Herzerkrankung. *J Kardiologie* 2008;11-12:342-346.
- 320. Muendlein A, Geller-Rhomberg S, Stark N, Drexel H. Genetischer Hintergrund des (Nicht-) Ansprechens auf eine Lipidogrel-Therapie. *J Kardiologie* 2011;18:312-319
- 321. Saely CH, Drexel V, Vonbank A, Drexel H. Lipid management in Type-2-Diabetes: the case for combination therapy? *Therapy* 2011; 8:129-141.

Guidelines, Position Papers, Recommendations

- 322. Parhofer KG, Aguiar C, Banach M, Drexel H, Gouni-Berthold I, Pérez de Isla L, Rietzschel E, Zambon A, Ray KK. Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment. *Eur Heart J Cardiovasc Pharmacother.* 2025 Jul 7;11(4):367-379. doi: 10.1093/ehjcvp/pvaf007. PMID: 40052330; PMCID: PMC12231129
- 323. Sun Y, Hasegawa K, Drexel H. Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes? *Eur Heart J Cardiovasc Pharmacother.* 2024 Jul 16;10(4):278. doi: 10.1093/ehjcvp/pvae033. PMID: 38697932.
- 324. Drexel H, Mader A. Bempedoic Acid: How Will It Shape the Future Lipid-Lowering Landscape? Mode of Action, Evidence, and Clinical Use. *Cardiology.* 2024;149(1):71-77. doi: 10.1159/000535372.

325. Pogran E, Burger AL, Zweiker D, Kaufmann CC, Muthspiel M, Rega-Kaun G, Wenkstetten-Holub A, Wojta J, Drexel H, Huber K. Lipid-Lowering Therapy after Acute Coronary Syndrome. *J Clin Med*. 2024 Apr 1;13(7):2043. doi: 10.3390/jcm13072043.
326. Sayour NV, Paál ÁM, Ameri P, Meijers WC, Minotti G, Andreadou I, Lombardo A, Camilli M, Drexel H, Grove EL, Dan GA, Ivanescu A, Semb AG, Savarese G, Dobrev D, Crea F, Kaski JC, de Boer RA, Ferdinandy P, Varga ZV. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence. *Eur Heart J*. 2024 Apr 7;45(14):1224-1240.
327. Wascher TC, Stulnig TM, Saely CH, Stechemesser L; Ausschuss Leitlinien. Thrombozytenaggregationshemmer (Update 2023) [Inhibition of platelet aggregation (Update 2023)]. *Wien Klin Wochenschr*. 2023 Jan;135(Suppl 1):161-163. German. doi: 10.1007/s00508-023-02168-6. Epub 2023 Apr 20. PMID: 37101038; PMCID: PMC10133352.
328. Clodi M, Saely CH, Hoppichler F, Resl M, Steinwender C, Stingl H, Wascher TC, Winhofer Y, Sourij H. Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023) [Diabetes mellitus, coronary artery disease and heart disease (Update 2023)]. *Wien Klin Wochenschr*. 2023 Jan;135(Suppl 1):201-206. German. doi: 10.1007/s00508-023-02183-7. Epub 2023 Apr 20. PMID: 37101042; PMCID: PMC10133371.
329. Huber J, Smeikal M, Saely CH, Stingl H, Clodi M, Lechleitner M, Fasching P. Geriatriische Aspekte bei Diabetes mellitus (Update 2023) [Geriatric aspects for the management of diabetes mellitus (Update 2023)]. *Wien Klin Wochenschr*. 2023 Jan;135(Suppl 1):307-318. German. doi: 10.1007/s00508-022-02124-w. Epub 2023 Apr 20. PMID: 37101051; PMCID: PMC10133361.
330. Clodi M, Abrahamian H, Brath H, Schernthaner G, Brix J, Ludvik B, Drexel H, Saely CH, Fasching P, Rega-Kaun G, Föger B, Francesconi C, Fröhlich-Reiterer E, Kautzky-Willer A, Harreiter J, Luger A, Resl M, Riedl M, Winhofer Y, Hofer SE, Hoppichler F, Huber J, Kaser S, Ress C, Lechleitner M, Aberer F, Mader JK, Sourij H, Toplak H, Paulweber B, Stechemesser L, Pieber T, Prager R, Stingl H, Stulnig T, Rami-Merhar B, Drexel H, Roden M, Schelkshorn C, Wascher TC, Weitgasser R, Zlamal-Fortunat S. Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023) [Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023)]. *Wien Klin Wochenschr*. 2023 Jan;135(Suppl 1):32-44. German. doi: 10.1007/s00508-023-02186-4. Epub 2023 Apr 20. PMID: 37101023; PMCID: PMC10133357.
331. Saely CH, Schernthaner GH, Brix J, Klauser-Braun R, Zitt E, Drexel H, Schernthaner G. Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023) [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)]. *Wien Klin Wochenschr*. 2023 Jan;135(Suppl 1):147-156. German. doi: 10.1007/s00508-023-02189-1. Epub 2023 Apr 20. PMID: 37101036; PMCID: PMC10133364.

332. Wascher TC, Paulweber B, Toplak H, Saely CH, Drexel H, Föger B, Hoppichler F, Stulnig T, Stingl H, Clodi M; Ausschuss Leitlinien. Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2023) [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2023)]. Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):157-160. German. doi: 10.1007/s00508-023-02166-8. Epub 2023 Apr 20. PMID: 37101037; PMCID: PMC10133339.
333. Cejka D, Wakolbinger-Habel R, Zitt E, Fahrleitner-Pammer A, Amrein K, Dimai HP, Muschitz C. Diagnose und Therapie der Osteoporose bei Patienten mit chronischer Niereninsuffizienz: Gemeinsame Leitlinie der Österreichischen Gesellschaft für Knochen- und Mineralstoffwechsel (ÖGKM), der Österreichischen Gesellschaft für Physikalische Medizin und Rehabilitation (ÖGPMR) und der Österreichischen Gesellschaft für Nephrologie (ÖGN) [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)]. Wien Med Wochenschr. 2022 Dec 21. German. doi: 10.1007/s10354-022-00989-0. Epub ahead of print. PMID: 36542221
334. Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, Kurpas D, Niessner A, Schiele F, Semb AG, Sionis A, Claeys MJ, Barrabes J, Montero S, Sinnaeve P, Pedretti R, Catapano A. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):939-949. doi: 10.1093/ehjacc/zuac123. PMID: 36574353
335. Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böhm M, Butler J, Carapetis J, Ceconi C, Chioncel O, Coats A, Crespo-Leiro MG, de Simone G, Drexel H, Emdin M, Farmakis D, Halle M, Heymans S, Jaarsma T, Jankowska E, Lainscak M, Lam CSP, Løchen ML, Lopatin Y, Maggioni A, Matrone B, Metra M, Noonan K, Pina I, Prescott E, Rosano G, Seferovic PM, Sliwa K, Stewart S, Uijl A, Vaartjes I, Vermeulen R, Verschuren WM, Volterrani M, Von Haehling S, Hoes A. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022 Feb 19;29(1):275-300. doi: 10.1093/eurjpc/zwab147. PMID: 35083485
336. El Hadidi S, Rosano G, Tamargo J, Agewall S, Drexel H, Kaski JC, Niessner A, Lewis BS, Coats AJS, Savarese G. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):187-210. doi: 10.1093/ehjcvp/pvaa108. PMID: 32941594
337. Milbradt S, Eichhorn J, Fetzner U, Fietz R, Gross R, Jung K, Klement M, Konzett K, Larcher B, Manz B, Mareth C, Schmieder E, Severgnini L, Sternbauer S, Wehrli MRT, Weifenbach N,

- Saely C, Drexel H. Correlation between the level of evidence and the class of recommendations concerning the pharmacological aspects of the Guidelines of the European Society of Cardiology. *Int J Cardiol.* 2022 Dec 16;S0167-5273(22)01901-5. doi: 10.1016/j.ijcard.2022.12.027. Epub ahead of print. PMID: 36535563
338. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J Cardiovasc Pharmacother.* 2022 Jan 5;8(1):100-103. doi: 10.1093/ehjcvp/pvab063. PMID: 34463331
339. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J Cardiovasc Pharmacother.* 2022 Jan 5;8(1):85-99. doi: 10.1093/ehjcvp/pvab018. Erratum in: *Eur Heart J Cardiovasc Pharmacother.* 2022 Dec 15;9(1):116. PMID: 33638977.
340. Piepoli MF, Adamo M, Barison A, Bestetti RB, Biegus J, Böhm M, Butler J, Carpets J, Ceconi C, Chioncel O, Coats A, Crespo-Leiro MG, de Simone G, Drexel H, Emdin M, Farmakis D, Halle M, Heymans S, Jaarsma T, Jankowska E, Lainscak M, Lam CSP, Løchen ML, Lopatin Y, Maggioni A, Matrone B, Metra M, Noonan K, Pina I, Prescott E, Rosano G, Seferovic PM, Sliwa K, Stewart S, Uijl A, Vaartjes I, Vermeulen R, Monique Verschuren WM, Volterrani M, von Heahling S, Hoes A. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. *Eur J Heart Fail.* 2022 Jan;24(1):143-168. doi: 10.1002/ejhf.2351. PMID: 35083829.
341. Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, Collet JP, Drexel H, Espinola-Klein C, Lewis BS, Roffi M, Sibbing D, Sillesen H, Stabile E, Schlager O, De Carlo M. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. *Eur Heart J.* 2021 Oct 14;42(39):4013-4024. doi: 10.1093/eurheartj/ehab390. PMID: 34279602
342. Aversa M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, Magni P, März W, Masana L, Mello E Silva A, Reiner Z, Ros E, Vrablik M, Zambon A, Zamorano JL, Stock JK, Tokgözoğlu LS, Catapano AL. Practical guidance for combination lipid- modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. *Atherosclerosis.* 2021 May;325:99-109. doi: 10.1016/j.atherosclerosis.2021.03.039. Epub 2021 Apr 13. PMID: 33892925

343. Drexel H, Coats AJS, Spoletini I, Bilato C, Mollace V, Perrone Filardi P, Rosano GMC. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. *Eur Heart J Cardiovasc Pharmacother*. 2020 Apr 1;6(2):115-121. doi: 10.1093/ehjcvp/pvz079. Erratum in: *Eur Heart J Cardiovasc Pharmacother*. 2020 Sep 1;6(5):291. PMID: 31873726
344. Drexel H, Milbradt S. ESC Guidelines revisited. *Eur Heart J Cardiovasc Pharmacother*. 2020 Apr 1;6(2):125. doi: 10.1093/ehjcvp/pvz083. PMID: 31930339
345. Drexel H, Milbradt S. ESC Guidelines revisited. *Eur Heart J Cardiovasc Pharmacother*. 2020 Jan 13. pii: pvz083
346. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020 Jan 1;41(1):111-188.
347. Drexel H, Coats AJS, Spoletini I, Bilato C, Mollace V, Filardi PP, Rosano GMC. ESC Position Paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome. *Eur Heart J Cardiovasc Pharmacother*. 2020 Apr 1;6(2):115-121
348. Weber T, Arbeiter K, Ardelt F, Auer J, Aufricht C, Brandt MC, Dichtl W, Ferrari J, Föger B, Henkel M, Hohenstein-Scheibenecker K, Horn S, Kautzky-Willer A, Kepplinger E, Knoflach M, Koppelstätter C, Mache C, Marschang P, Mayer G, Metzler B, Oberbauer R, Obermair F, Obermayer-Pietsch B, Perl S, Pilz S, Prischl FC, Podczek-Schweighofer A, Rebhandl E, Rohla M, Roller-Wirnsberger R, Saely CH, Siostrzonek P, Slany J, Stoschitzky K, Waldegger S, Wenzel RR, Weiss T, Wirnsberger G, Winhofer-Stöckl Y, Zweiker D, Zweiker R, Watschinger B; Österreichische Gesellschaft für Hypertensiologie; Österreichische Atherosklerosegesellschaft; Österreichische Diabetes Gesellschaft; Österreichische Gesellschaft für Internistische Angiologie; Österreichische Gesellschaft für Nephrologie; Österreichische Kardiologische Gesellschaft; Österreichische Gesellschaft für Neurologie; Österreichische Schlaganfall-Gesellschaft; Österr. Gesellschaft für Allgemeinmedizin; Österr. Gesellschaft für Geriatrie; Österreichische Gesellschaft für Endokrinologie und Stoffwechsel; Österreichische Gesellschaft für Innere Medizin; Österreichische Gesellschaft für Kinder- und Jugendheilkunde. [Austrian Consensus on High Blood Pressure 2019]. *Wien Klin Wochenschr*. 2019 Nov;131(Suppl 6):489-590
349. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani

- M, Voors AA, Filippatos G, Coats AJS. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2019 Oct;21(10):1169-1186
350. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. *Eur Heart J Cardiovasc Pharmacother*. 2019 Jul 1;5(3):171-180
351. Clodi M, Abrahamian H, Brath H, Brix J, Drexel H, Fasching P, Föger B, Francesconi C, Fröhlich-Reiterer E, Harreiter J, Hofer SE, Hoppichler F, Huber J, Kaser S, Kautzky-Willer A, Lechleitner M, Ludvik B, Luger A, Mader JK, Paulweber B, Pieber T, Prager R, Rami-Merhar B, Resl M, Riedl M, Roden M, Saely CH, Schelkshorn C, Schernthaner G, Sourij H, Stechemesser L, Stingl H, Toplak H, Wascher TC, Weitgasser R, Winhofer-Stöckl Y, Zlamal-Fortunat S. [Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2019)]. *Wien Klin Wochenschr*. 2019 May;131(Suppl 1):27-38
352. Schernthaner G, Saely CH, Schernthaner GH, Watschinger B, Drexel H. [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)]. *Wien Klin Wochenschr*. 2019 May;131(Suppl 1):124-135. doi: 10.1007/s00508-019-1460-2.
353. Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. *Eur Heart J Cardiovasc Pharmacother*. 2018 Jul 1;4(3):180-188. doi: 10.1093/ehjcvp/pvy015
354. Niessner A, Tamargo J, Koller L, Saely CH, Schmidt TA, Savarese G, Wassmann S, Rosano G, Ceconi C, Torp-Pedersen C, Kaski JC, Kjeldsen KP, Agewall S, Walther T, Drexel H, Lewis BS. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J*. 2018 Jun 21;39(24):2274-2281.
355. Drexel H. Cost-effectiveness with PCSK9 inhibitors: a matter of costs. *Eur Heart J Cardiovasc Pharmacother*. 2018 Jan 1;4(1):23-24

356. Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saely CH, Drexel H. Comprehensive efforts to increase adherence to statin therapy. *Eur Heart J*. 2017 Aug 21;38(32):2473-2479.
357. Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp-Pedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GYH, Verheugt FWA, Agewall S. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. *Eur Heart J*. 2017 Jun 7;38(22):1710-1716.
358. Drexel H. A commentary on the new ESC guidelines on dyslipidaemias. *Eur Heart J Cardiovasc Pharmacother*. 2017 Apr 1;3(2):73-74
359. Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saely CH, Drexel H. Comprehensive efforts to increase adherence to statin therapy. *Eur Heart J*. 2017 PMID: 28077470
360. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias]. *Kardiol Pol*. 2016;74(11):1234-1318. PMID: 27910077
361. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis*. 2016 Oct;253:281-344. PMID: 27594540
362. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL; Authors/Task Force Members. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. 2016 Oct 14;37(39):2999-3058. PMID: 27567407
363. Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted ST, Torp-Pedersen C, Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GYH, Verheugt FWH, Agewall S. Reversal strategies for Non-vitamin K oral anticoagulants – a critical appraisal of available

- evidence and recommendations for the clinical management. *Eur H J* 2015, epub ahead of print
364. Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, Drexel H, Patak A, Torp-Pedersen C, Kjeldsen KP, Tamargo J. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC; *Eur Heart J* 2015; 36: 2677-2680.
365. Drexel H, Vonbank A, Fraunberger P, Riesen WF, Saely CH. Toward a more professional and practical medical education: a novel Central European approach. *Adv Med Edu Pract* 2015; 6: 1-9.
366. Clodi M, Abrahamian H, Drexel H, Fasching P, Hoppichler F, Kautzky-Willer A, Lechleitner M, Ludvik B, Prager R, Roden M, Saely CH, Schernthaner G, Schober E, Toplak H, Wascher T, Weitgasser R. Antihyperglycemic Treatment Guidelines for diabetes mellitus type 2. *Wien Klin Wochenschr* 2012; 124, Suppl 2: 10-16.
367. Schernthaner G, Drexel H, Rosenkranz AR, Schernthaner GH, Watschinger B. Antihypertensive therapy in diabetes mellitus: 2012 guidelines of the Austrian diabetes association. *Wien Klin Wochenschr* 2012; 124, Suppl 2: 23-27.
368. Saely CH, Drexel H. Lipid therapy in patients with diabetes. *Wien Med Wochenschr* 2010;160:25-29. PMID: 20229158.
369. Drexel H. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? *Fundam Clin Pharmacol* 2009;23:687-692.
370. Drexel H. Nicotinic acid in the treatment of hyperlipidaemia. *Fundam Clin Pharmacol* 2007;21 Suppl 2:5-6.
371. Drexel H. Reducing risk by raising HDL-cholesterol: the evidence. *Eur Heart J* 2006;8:F23-F29.
372. Sheperd J, Betteridge J, Van Gaal L on behalf of a European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. *Curr Med Res Opin* 2005;21:665-682.
373. Drexel H. Modern intervention strategies for managing dyslipidaemia: the case for combination therapy. *Br J Diabetes Vasc Dis* 2005;5:S17-S23.
374. Lechleitner M, Drexel H. Diabetes and lipids. *Wien Med Wochenschr* 2003;153:469-473.

Letters, Editorials

375. Drexel H, Festa A, Atar D. Clinical science at the intersection of cardiovascular, metabolic and renal diseases: new approaches. *Cardiology*. 2025 Aug 7;1-5. doi: 10.1159/000547405. Epub ahead of print. PMID: 40790846.
376. Leiherer A. Special Issue "Machine Learning and Bioinformatics in Human Health and Disease"-Chances and Challenges. *Int J Mol Sci*. 2024 Nov 28;25(23):12811. doi: 10.3390/ijms252312811. PMID: 39684521; PMCID: PMC11641040
377. Festa A, Saely CH, Drexel H. Sodium-glucose co-transporter-2 inhibitors: Writing the next chapter of a unique success story. *Diabetes Obes Metab*. 2024 Nov;26(11):4816-4819. doi: 10.1111/dom.15909. Epub 2024 Sep 2. PMID: 39223853.
378. Drexel H, Festa A. Subclinical atherosclerosis: More data - More insights into prevention. *Atherosclerosis*. 2024 Jun;393:117561. doi: 10.1016/j.atherosclerosis.2024.117561.
379. Niessner A, Drexel H. PCSK9 inhibition in patients with heart failure: neutral or harmful intervention? *Eur Heart J*. 2022 Apr 19;43(16):1566-1568. doi: 10.1093/eurheartj/ehab913. Erratum in: *Eur Heart J*. 2022 Feb 15;; PMID: 35029276
380. Muendlein A, Ebner J, Zitt E. Prevalence of the Janus Kinase 2 V617F Mutation in Patients with End-Stage Renal Disease. *Nephron*. 2016 Nov 26. PMID: 27889755
381. Saely CH, Drexel V, Drexel H. The fate of fat: A response. *Gerontology* 2011; 58: 123-125.
382. Saely CH, Rein P, Drexel H. Combination lipid therapy in type 2 diabetes. *N Engl J Med* 2010;363:692
383. Winder T, Scheithauer W, Lang A. Comment on Karapetis et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. *N Engl J Med* 2009; 360: 834-835.
384. Saely CH, Marte T, Drexel H. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. *N Engl J Med* 2004;350:1150-1152
385. Risch L, Drexel H, Huber AR. Cystatin C and the risk of death. *N Engl J Med* 2005;353:842-844.
386. Hoefle G, Holzmueller H, Drexel H. Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation. *N Engl J Med* 2004;350:2306-2308.
387. Hofle G, Holzmuller H, Drexel H. Bisphosphonates routine in prevention of post-transplant osteoporosis? *J Bone Miner Res* 2005;20:1482.

Clinical Trials

388. Daniel-Fischer L, Antlanger M, Cejka D, Eller K, Gauckler P, Odler B, Rudnicki M, Säemann MD, Schmidt A, Sunder-Plassmann G, Wiesholzer M, Windpessl M, Zitt E, Koenig F, Greenbaum LA, Kronbichler A, Aufricht C. Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design. *Kidney Int Rep.* 2023 Nov 3;9(2):478-481. doi: 10.1016/j.ekir.2023.10.027. eCollection 2024 Feb. PMID: 38344717
389. Sourij C, Oulhaj A, Aziz F, Tripolt NJ, Aberer F, Pferschy PN, Postula M, Drexel H, Benedikt M, Kolesnik E, Pieber TR, Bugger H, von Lewinski D, Sourij H. Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post-hoc analysis of the EMMY trial. *Diabetes Obes etab.* 2024 May;26(5):1971-1975. doi: 10.1111/dom.15477.
390. Ebenbichler C, Drexel H, Hanusch U, Toplak H, Dhalwani NN, Bridges I, Hoelzl R, Hemetsberger M, Ray KK. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study. *Wien Klin Wochenschr.* 2023 Jul 31. doi: 10.1007/s00508-023-02245-w. Epub ahead of print. PMID: 37525072.
391. Von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, Alber H, Berger R, Lichtenauer M, Saely CH, Moertl D, Auersperg P, Reiter C, Rieder T, Siller-Matula JM, Gager GM, Hasun M, Weidinger F, Pieber TR, Zechner PM, Herrmann M, Zirlik A, Holman RR, Oulhaj A, Sourij H. Empagliflozin in acute myocardial infarction: the EMMY trial. *Eur Heart J.* 2022 Nov 1;43(41):4421-4432. doi: 10.1093/eurheartj/ehac494. PMID: 36036746; PMCID: PMC9622301.
392. Siostrzonek P, Brath H, Zweiker R, Drexel H, Hoelzl R, Hemetsberger M, Ray KK. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?: Results from the DA VINCI study. *Wien Klin Wochenschr.* 2022 Apr;134(7-8):294-301. doi: 10.1007/s00508-021-01978-w. Epub 2021 Dec 6. PMID: 34870742; PMCID: PMC9023395
393. Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C, Leitner K, Lichtenauer M, Mader A, Moertl D, Oulhaj A, Reiter C, Rieder T, Saely CH, Siller-Matula J, Weidinger F, Zechner PM, von Lewinski D, Sourij H; EMMY study group. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute Myocardial infarction-The EMMY trial. *Am Heart J.* 2020 Mar;221:39-47. doi: 10.1016/j.ahj.2019.12.004. Epub 2019 Dec 12. PMID: 31901799
394. Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C, Leitner K, Lichtenauer M, Mader A, Moertl D, Oulhaj A, Reiter C, Rieder T, Saely CH, Siller-Matula J, Weidinger F, Zechner PM, von Lewinski D, Sourij H; EMMY study

- group. Impact of EMPagliflozin on cardiac function and biomarkers of heart failure in patients with acute Myocardial infarction-The EMMY trial. *Am Heart J.* 2020 Mar;221:39-47.
395. Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner Ž, Roe MT, Tse HF, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Investigators. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. *Circulation.* 2019 Dec 17;140(25):2054-2062. doi: 10.1161/CIRCULATIONAHA.119.043826. Epub 2019 Nov 11 PubMed PMID: 31707788; PubMed Central PMCID: PMC6919220
396. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA; THEMIS Steering Committee and Investigators. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. *N Engl J Med.* 2019 Oct 3;381(14):1309-1320
397. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. *Lancet.* 2019 Sep 28;394(10204):1169-1180. doi: 10.1016/S0140-6736(19)31887-2.
398. Sulzgruber P, Wassmann S, Semb AG, Doehner W, Widimsky P, Gremmel T, Kaski JC, Savarese G, Rosano GMC, Borghi C, Kjeldsen K, Torp-Pedersen C, Schmidt TA, Lewis BS, Drexel H, Tamargo J, Atar D, Agewall S, Niessner A. Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1. *Eur Heart J.* 2019 Sep 21;40(36):3010-3012
399. Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, Schröder H, Jaehnig P, Potthoff K, Lerchenmüller C. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer. *Breast Cancer Res Treat.* 2019 Aug;176(3):637-647
400. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol.* 2019 Aug;7(8):618-628. doi: 10.1016/S2213-

- 8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;.: Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21
401. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N Engl J Med*. 2018 Nov 29;379(22):2097-2107
402. Sawhney JP, Kothiwale VA, Bisne V, Durgaprasad R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawla K, Allu J, Pieper KS, John Camm A, Kakkar AK; GARFIELD-AF Investigators. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. *Indian Heart J*. 2018 Nov - Dec;70(6):828-835
403. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2017 Sep 28;377(13):1228-1239
404. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, Ceconi C, Drexel H, Kjeldsen K, Savarese G, Torp-Pedersen C, Atar D, Lewis BS, Agewall S. Gender differences in the effects of cardiovascular drugs. *Eur Heart J Cardiovasc Pharmacother*. 2017 Jul 1;3(3):163-182
405. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McEneaney E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. *N Engl J Med*. 2017 May 18;376(20):1933-1942.
406. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *NEJM* 2015; 373: 2117-2128.
407. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin
408. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators.; ROCKET AF Steering Committee

- Investigators.. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. *J Am Heart Assoc.* 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197. PubMed PMID: 26955859; PubMed Central PMCID: PMC4943233.
409. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA; ODYSSEY ALTERNATIVE Investigators.. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol.* 2015 Nov-Dec;9(6):758-69. doi: 10.1016/j.jacl.2015.08.006. PubMed PMID: 26687696.
410. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med.* 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. PubMed PMID: 26039521.
411. Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, vanEickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators.. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes.* 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/CIRCOUTCOMES.114.001556. PubMed PMID: 25714828.
412. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Circulation.* 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. PubMed PMID: 24895454.
413. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med.* 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. PubMed PMID: 23126252.
414. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE

- Investigators.. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. PubMed PMID: 23121378.
415. ORIGIN Trial Investigators., Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. PubMed PMID: 22686416.
416. ORIGIN Trial Investigators., Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggioni AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *N Engl J Med*. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. PubMed PMID: 22686415.
417. EINSTEIN–PE Investigators., Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med*. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. PubMed PMID: 22449293.
418. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.. Vorapaxar in the secondary prevention of atherothrombotic events. *N Engl J Med*. 2012 Apr 2;366(15):1404-13. doi: 10.1056/NEJMoa1200933. PubMed PMID: 22443427.
419. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee investigators.. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. *Lancet Neurol*. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. PubMed PMID: 22402056.
420. Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators.. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. *Eur Heart J*. 2012 Apr;33(7):857-65. doi: 10.1093/eurheartj/ehs019. PubMed PMID: 22345126; PubMed Central PMCID: PMC3345558.
421. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. PubMed PMID: 21830957.

422. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldles M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators.. Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med*. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. PubMed PMID: 21780946.
423. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. *Am Heart J*. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017. PubMed PMID: 19958854.
424. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators., Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. PubMed PMID: 19717846.
425. APPRAISE Steering Committee and Investigators., Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. *Circulation*. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. PubMed PMID: 19470889.
426. Brugts JJ, de Maat MP, Boersma E, Witteman JC, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AH, Simoons ML; EUROPA-PERGENE investigators.. The rationale and design of the PERindopril GENetic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. *Cardiovasc Drugs Ther*. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. PubMed PMID: 19082699.
427. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators.. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). *Diabetes Care*. 2007 Nov;30(11):2773-8. PubMed PMID: 17666462.

428. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators.. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. *J Am Coll Cardiol*. 2007 May 1;49(17):1772-80. PubMed PMID: 17466227.
429. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. *Lancet*. 2005 Oct 8;366(9493):1279-89. PubMed PMID: 16214598.

Other Articles

430. Burger AL, Auer J, Binder CJ, Bonderman D, Drexel H, Fasching P, Ludvik B, Schernthaner GH, Serles W, Siostrzonek P, Stulnig T, Huber K. Innovative Lipidtherapie bei kardiovaskulären Risikopatienten // Innovative lipid therapy in cardiovascular risk patients *Journal für Kardiologie - Austrian Journal of Cardiology* 2022; 29 (5-6), 138-145
431. Huber K, Drexel H, Alber H, Auer J, Delle Karth G, Ebenbichler C, Fasching P, Globits S, Hödl R, Hoppichler F, Lang W, Ludvik B, Metzler B, Podcizek-Schweighofer A, Roithinger FX, Saely CH, Schernthaner GH, Silbernagel G, Siostrzonek P, Speidl WS, et al. Praktische Umsetzung der Richtlinien zur LDL-C-Senkung 2020 // Practical realization of ESC-Guidelines to reduce LDL-cholesterol. *Zeitschrift für Gefäßmedizin* 2020; 17 (2), 16-22
432. J. F. Dopheide, H. Drexel. Lipidsenkende Therapie zur Sekundärprävention der peripheren arteriellen Verschlusskrankheit. *Gefäßchirurgie* Ausgabe: 3/2020
433. Niessner A, Sulzgruber P, Alber H, Altenberger J, Clodi M, Fasching P, Francesconi C, Kautzky-Willer A, Mayer G, Podcizek-Schweighofer A, Wapnash L, Drexel H, Koller L, Wascher TC, Huber K. Antidiabetische Medikation von Patienten mit kardiovaskulärer Erkrankung – Zusammenfassung der Literatur und Anwendung in der klinischen Praxis // Antidiabetic Therapy of Patients with Cardiovascular Disease. *Journal für Kardiologie - Austrian Journal of Cardiology* 2018; 25 (5-6), 124-127
434. Säly CH, Säly RR, Drexel H. Die neuen ESC-Guidelines zur Prävention: Wie soll eine Hyperlipidämie behandelt werden? // The New ESC Guidelines on Prevention: How to Treat Hyperlipidemia? *Journal für Kardiologie - Austrian Journal of Cardiology* 2017; 24 (5-6), 88-92

- 435. Saely CH, Vathie K, Drexel H. Ischemic heart disease in diabetes. Textbook of diabetes and ischemic heart disease 2016
- 436. Saely CH. Konsequente LDL-Cholesterinsenkung für den kardiovaskulären Patienten. Je niedriger, desto besser. WMW Skriptum. Band 13/ Heft 01
- 437. Saely CH. Kardiovaskuläre Trials mit Antidiabetika - Löst die Glukosesenkung das Problem? Der informierte Arzt 2016; 6: 16-19.
- 438. Drexel H, Saely CH. Kardiovaskuläre Effekte von SGLT-2-Hemmern. Der Diabetologe 2016; 12(3), 195-200. DOI 10.1007/s11428-016-0079-4
- 439. Drexel H, Scherbaum WA. Kardiovaskuläre Effekte von Antidiabetika. Der Diabetologe 2016; 12(3), 150-153. 10.1007/s11428-016-0089-2
- 440. Saely CH. LDL-Cholesterin: „The lower, the better“. Nephro Script 4/2015: 12-15.
- 441. Lhotta K. Der Kardiologe sagt: Harnsäure runter, was sagt der Nephrologe? Überlegungen zum Management bei kardiovaskulären Hochrisikopatienten. Nephro Script 4/2015: 10-11.
- 442. Zitt E. Parathyreoidektomie – was bringt es? Nephro Script 4/2015: 18-20.
- 443. Saely CH. Stellenwert der Triglyzeridsenkung im modernen Lipidmanagement. Expertenkommentar. MEDahead report Kardiologie 2015.
- 444. Saely CH. Familiäre Hypercholesterinämie im Fokus. Intern (Journal des Berufsverbandes Österreichischer Internisten) 1/2015; 1-8.
- 445. IMPROVE-IT has proven it: noch niedriger ist noch besser. Expertenkommentar. Universum Innere Medizin 1/2015:58-61.
- 446. Vonbank A. Kardiovaskuläre Risikofaktoren als Therapieziel. Diabetesforum 3/2015: 50-51.
- 447. Saely CH. Schlaganfallprävention bei Vorhofflimmern: DOAKs aus der kardiologischen Perspektive. Medical Tribune 2014; 44: 16.
- 448. Consensus Statement; Expertenboard-Meeting Oktober 2014 in Wien: Die optimale Therapie der Thrombozytenaggregationshemmung, Expertenkommentar: 1-4.
- 449. Drexel H. Editorial: Elevation of HDL – Will the promise be fulfilled? Journal für Kardiologie 2014; 21: 251-252.
- 450. Drexel H, Saely CH. Paradigmenwechsel in der Lipidtherapie. Universum Innere Medizin 02/2014: 39-43.
- 451. Drexel H., Saely CH. Neue Antidiabetika: Bedeutung der Glukosesenkung im Management des Typ 2 Diabetes. Medinfo Ärzteverlag 2014. 4(3): 18-20.
- 452. Drexel H. Kardiodiabetes – Was gibt es Neues? Skriptum Wiener Medizinische Wochenschrift 1/2014: 22.

453. Drexel H. Kommentar zu LDL-C-Zielwerterreichung: Es gibt noch viel zu tun. *Universum Innere Medizin* 1/2014: 41.
454. Drexel H. Expertenkommentar zu „Mit Brilique TM (Ticagrelor) die kardiovaskuläre Mortalität von Patienten mit akutem Koronarsyndrom senken“: MEDahead Publikation 2014: 8.
455. Saely CH. Expertenmeeting: Doppelfunktion des Pankreas - Interaktionen zwischen exokriner und endokriner Funktion, Diagnostische Herausforderungen. Veranstaltungsreport 2013 bei der 41. ÖDG Jahrestagung: 3.
456. Drexel H. Interview mit Peter Hopfinger hinsichtlich ÖDG Präsidenschaft und ÖDG-Frühjahrestagung 2013. *Diabetes Austria* April 2013
457. Saely CH, Drexel H. Medikamentös induzierter Diabetes. *Ärztewoche* 2013; 18: 14.
458. Drexel H, Säly CH. Die Relevanz der Lipidtherapie beim PAVK-Patienten -- Statine als Behandlungsgrundlage. *Universum Innere Medizin* 02/2013: 42.
459. Drexel H. Kampf gegen Kalorien: Steuern mit Steuern? *Ärztewoche* 2013; 50-52: 2.
460. Saely CH. Expertenmeeting: Doppelfunktion des Pankreas - Interaktionen zwischen exokriner und endokriner Funktion, Diagnostische Herausforderungen. Veranstaltungsreport 2013 bei der 41. ÖDG Jahrestagung: 3.
461. Drexel H. Statine auch bei Methusalem hilfreich. *Ärztemagazin* 2013; 27: 41.
462. Drexel H und Saely CH. Neues zum Welt-Diabetes-Tag - L wie Lebensstil und LDL-Cholesterin. *Medical Tribune* 2013; 49: 21.
463. Drexel H. ÖDG Aktuell - Ausblick auf die Funktionsperiode 2012/2013. *DIABETES FORUM* 1/2012:7.
464. Saely CH, Drexel H. Bewährte und neue Präventionsziele bei kardiovaskulären Erkrankungen. *Wien Med Wochenschr* 2012;1:31.
465. Saely CH. Kongressbericht: Top Cardiologists' Meeting zum Thema „Therapieresistente arterielle Hypertonie: Renale Sympathikusdenervation“ *J. Kardiologie*. 2012; 19 (11-12): 348-350
466. Saely CH, Drexel V, Drexel H. Herzinsuffizienz und Diabetes. *Wien Med Wochenschr* 2012;8:13-16.
467. Gahr S, Saely CH, Drexel H. Ernährungsumschau 03/2012: 148-153.
468. Drexel H. Stellenwert der Therapie mit Mischinsulin bei Typ-2-Diabetes. *MEDahead Report* 2012.
469. Drexel H. Medizinischer Newsletter für zukunftsorientierte Ärzte. Der Typ-2-Diabetiker – ein kardiovaskulärer Hochrisikopatient. *MEDahead Report, Expertenkommentar* 2012

470. Drexel H. Expertenumfrage: Pioglitazon – Mythen und Fakten: Stellenwert von Pioglitazon in der Therapie des Typ-2-Diabetes, *Universum Innere Medizin* 9/12
471. Drexel H. Erfolgsgeschichte Diabetologie. *Apothekerkrone* 20/2012: 21 – 23.
472. Saely CH. Lipidtherapie in der Angiologie. *MEDahead Positionspapier* 9/2012:1-6.
473. Drexel H. Die Feinde der Arterien – wie halte ich sie im Zaum?
Universum Innere Medizin 07/12: 24.
474. Saely CH, Drexel H. Sicherheit und Effektivität in der Diabetestherapie: orale Antidiabetika.
Jatros Diabetes und Stoffwechsel 3/2012: 8-9.
475. Drexel H. Erfolgreiche Diabetestherapie in Österreich. *Jatros Diabetes und Stoffwechsel* 3/2012: 6-7.
476. Positionspapier. Pharmakologische Spezifika und klinischer Stellenwert von Linagliptin (Trajenta®) bei Typ-2-Diabetes. *MEDahead* März 2012 (in press).
477. Interview mit Drexel H, Clodi M. Therapie: „aktiv“? *ADA Journal* 01/2012:6-7.
478. Drexel H. Kardiovaskuläres Risiko. *Suppl. Ärztemagazin Takeda Diabetesforum* 2012;
479. Drexel H, Saely CH. Strengere Zielwerte für Hochrisikopatienten sind sinnvoll. *Universum Innere Medizin*. 05/12:52.
480. Beer S, Drexel H. Individuelle Therapie der postmenopausalen Osteoporose. *Ärztekrone Osteoporose*/2012:12.
481. Drexel H. Saely CH. Zum Geleit – Was erwartet Sie in diesem Heft? *Diabetes Forum* 3/2012:25.
482. Saely CH, Drexel H. Lipidtherapie bei Diabetes – Warum ein LDL-Cholesterin von < 70 mg/dl? *Diabetes Forum* 3/2012:38-40.
483. Sturn D, Saely CH, Drexel H. Diabetes und Herzinsuffizienz – Neue Therapieansätze. *Diabetes Forum* 3/2012:48-51.
484. Wascher TC, Paulweber B, Toplak H, Saely CH, Drexel H. Lipids: diagnosis and therapy in type 2 diabetes. *Wien Klin Wochenschr* 2012; 124, Suppl 2: 28-30.
485. Drexel H, Saely CH. Glitazone - Was jeder Kardiologe wissen sollte. *Wien Med Wochenschr* 2011;1:14-16.
486. Drexel H. Experten-Statement: Einmal wöchentlich Exenatid (Bydureon®): Studienlage und Einschätzung österreichischer Experten. *MEDahead*, Juni 2011.
487. Drexel H. Experten-Statement: Mit Ticagrelor (Brilique TM) die kardiovaskuläre Mortalität von Patienten mit akutem Koronarsyndrom senken. *MEDahead advice Kardiologie*, 2011:9.

488. Drexel H. Experten-Statement: Stellenwert von Twynsta[®] (Telmisartan + Amlodipin) im Management der Hypertonie. Update Europe, Internationale Zeitschrift für ärztliche Fortbildung 8/August 2011.
489. Drexel H. Workshop Angiogathie – Umfassende Gefäßprotektion bei Typ-2-Diabetes. In: Die Gefäße im Fokus – Internisten-Symposion & Workshops, Schloss Fuschl Resort
490. Saely CH, Drexel H. Diabetes und pAVK – Brauchen wir den Ankle-Brachial-Index? JATROS Diabetes & Stoffwechsel 4/2011;8-9.
491. Drexel H. Experten-Statement: Stellenwert der oszillometrischen Messung des Ankle Brachial Index (ABI) bei Patienten mit Verdacht auf pAVK. Update, Internationale Zeitschrift für ärztliche Fortbildung 7/Juni 2011.
492. Beer S. Individuelle Therapie der postmenopausalen Osteoporose. Endokrinologie & Stoffwechsel. Universum Innere Medizin 03/11, 30-31.
493. Drexel H, Saely CH. Glitazone: Was jeder Kardiologe wissen sollte. Skriptum Kongressjournal, Wiener Medizinische Wochenschrift 1/2011, 14-16.
494. Drexel H. Expertenforum: Stellenwert von Dronedaron bei Vorhofflimmern. Universum Innere Medizin 04/11, 32.
495. Saely C, Drexel H. Unterzucker bei Insulintherapie. Ärzte Woche (22) 2011, 25. Jg.: 14.
496. Saely CH, Drexel V, Vonbank A, Drexel H. Lipid management in Type 2 diabetes: the case for combination therapy? Therapy 8 (2) 2011: 129-141
497. Drexel H, Saely CH, Rein P. Aktuelles aus der kardiometabolischen Forschung. Universum Innere Medizin, 2011; 3:Expertenforum.
498. Drexel H, Saely CH. Strategien der intensivierten Lipidtherapie. Universum Innere Medizin, 2011; 2:32-36.
499. Drexel H. Disease Management des Typ 2 Diabetes – Hypertonie: Welche Medikation führt zum Ziel? Arzt & Praxis, 2011; 65 (973): 92-94.
500. Mündlein A; Geller-Rhomberg S; Stark N; Drexel H. Genetischer Hintergrund des (Nicht-) Ansprechens auf eine Clopidogrel-Therapie. Journal für Kardiologie - Austrian Journal of Cardiology 2011; 18 (9-10): 312-319
501. Drexel H, Saely CH. Statine als Basis des modernen Lipidmanagements - Strategien der intensivierten Lipidtherapie. Universum Innere Medizin, 2011; 2: 18-20.
502. Fraunberger P., Drexel H., Walli A.K., Pathophysiologie der Sepsis und deren mögliche Beeinflussung durch HMG-CoA-Reduktase-Inhibitoren, Deutsche Medizinische Wochenschrift, 2010; 135: 2128-2132 (Sonderdruck Thieme-Verlag)

503. Saely CH, Drexel H. Bedeutung der Lipidtherapie bei Diabetes. Wiener Medizinische Wochenschrift, 2010; 1-2: 25-29.
504. Drexel H, Saely CH. Optimale Lipid-Therapie 2010. Wiener Medizinische Wochenschrift (Kongressjournal), 2010; 2:19-22.
505. Saely CH, Drexel H. Management der Herzinsuffizienz aus diabetologischer Sicht. Diabetes Forum 2010; 1: 24-30.
506. Saely CH, Drexel H. Adipositas: Risikofaktor für Diabetes und koronare Herzerkrankung. Jatro Diabetes & Stoffwechsel 2010; 2:28-31.
507. Saely CH, Drexel H. Diabetes und Herzinsuffizienz: Komorbidität vermeiden. Ärzte Krone 2010; 10: 10-14.
508. Saely CH, Drexel H. Adipositas: Risikofaktor für Diabetes und koronare Herzerkrankung. Jatro Kardiologie & Gefäßmedizin 2010; 2:8-10.
509. Drexel H, Saely CH. Lipide, CRP und Vascular Remodelling. Wiener Medizinische Wochenschrift (Kongressjournal) 2010; 6: 25-26.
510. Drexel H, Saely CH. Viele Wege führen zum Ziel – Optimale Lipidtherapie 2010. Universum Innere Medizin 2010; 6: 45-47.
511. Drexel H. Update vom Kardiologiekongress: Abwärtsgehen ist gut für die Herzgesundheit. Ärzte Krone 2010; 17: 52.
512. Saely CH. Kongressbereich: Top Cardiologist's Meeting zum Thema „Atherosklerose und Inflammation“. J Kardiol 2010; 17(9-10). 380-383.
513. Drexel H., Saely CH. Hypertonie bei Typ-2-Diabetes: Welche Medikation führt zum Ziel? Universum Innere Medizin 2010; 8: 40-42.
514. Saely CH, Drexel H. Prognostischer Stellenwert des HbA1c (2) – Evidenz aus makrovaskulären Endpunktstudien. Diabetes Forum 2010; 4: 40-44.
515. Drexel H. Prävention makrovaskulärer Komplikationen. Diabetes Forum 2010 Sonderausgabe: 28-32.
516. Saely CH, Mathies R, Drexel H. Strategien zur Verlangsamung der Atheroskleroseprogression. Universum Innere Medizin 2010; 9: 14.
517. Saely CH, Mathies R, Drexel H. Diabetes Typ 2 – Strategien zur Verlangsamung der Atheroskleroseprogression. Universum Innere Medizin 2010; 9: 14-16.
518. Saely CH. Bluthochdruck kann zu Erektionsstörungen führen. Lust und Frust. Forum Gesundheit 2010; 5: 33.
519. Drexel H, Saely CH. Strategien der intensivierten Lipidtherapie. Ärzte Krone 20/12: 30–32.
520. Drexel H. Stabile und instabile KHK. Universum Innere Medizin ÖGIM 07/13: 10-11.

521. Drexel H. Stabile und instabile KHK. Ärzteswoche Spezial ÖGIM 39: 32.
522. Saely CH. Hochdrucktherapie – Was bringt die Zukunft? LDL: The lower, the better. Ärztekron 19; 12-13.
523. Drexel H. Thrombozytenaggregationshemmung: Womit? Wieviel ist genug? Was ist zuviel? Riport 73:4.
524. Schmid F, Saely CH, Drexel H. Metabolisches Syndrom und antihypertensive Therapie. J Hypertonie; 17: 59-64.
525. Saely CH. Expertenkommentar. Bedeutung der kombinierten Lipidsenkung für die Zielwerterreichung und das kardiovaskuläre Risiko. 04/13.
526. Drexel H, Saely CH. Die Relevanz der Lipidtherapie beim pAVK-Patienten: Statine als Behandlungsgrundlage. Universum Innere Medizin 2/13: 63.
527. Drexel, Saely CH. Highlightbericht über die ÖDG-Frühjahrstagung, „Fortschritte in klinischer Diabetologie und Endokrinologie“. Universum Innere Medizin 03/13: 58-59.
528. Gouya G., Saely CH, „Hochdrucktherapie – was bringt die Zukunft? und „Aktuell gültige Guidelines zum Lipidmanagement“. Ärztekron 19/13: 12-15.
529. Beer S; Säly CH; Höfle G; Vonbank A; Breuss J; Gänsbacher B; Mündlein A; Drexel H. Erniedrigte Knochendichte bei Männern nicht mit angiographisch nachgewiesener koronarer Herzerkrankung assoziiert. Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen 2010; 17 (3): 118-119
530. Saely CH, Drexel H. Highlights - kardiovaskuläre Prävention. Wien Med Wochenschr 2009;7:14-16.
531. Drexel H, Saely CH. Lifestyle versus Medikamente. Wien Med Wochenschr 2009;7:20-22.
532. Drexel H, Saely CH. Fettgewebe - diabetische Dyslipidämie als Schnittpunkt zur Atherosklerose. Wien Med Wochenschr 2009;12:10-12. PMID: 20229158
533. Drexel H. Dyslipidämie als Schnittstelle zur Atherosklerose. Wien Klin Wochenschr 2009;21-22:4.
534. Bochdanský T, Boeckelberger M, Leube W, Solti K, Drexel H. Evaluation zweier interdisziplinärer Nachsorgestationen. Phys Med Rehab Kuror 2009;19:256-265.
535. Risch L, Saely CH, Drexel H. The medical laboratory in preventive care. Ther Umsch 2008;65:481-485. PMID: 18791961
536. Drexel H; Mündlein A; Winder T; Loacker S. Einfluss von DNA-Variationen auf die koronare Herzerkrankung. Journal für Kardiologie - Austrian Journal of Cardiology 2008; 15 (11-12): 342-346

537. Toplak H, Drexel H, Hoppichler F, Huber K, Ludvik B. Hochdosis-Statintherapie versus zaghafte Lipidintervention. *J Vask Med* 2008;2:19-21.
538. Saely CH, Drexel H. The Periscope study. *J Kardiolog* 2008;15:255-257.
539. Huber K, Baumgartner H, Darius H, Drexel H, Grimm M, Lang I, Metzler H, Mulac K, Pichler M, Watzke H, Weidinger F, Weihs W, Weltermann A, Wojta J, Zenker G, Christ G. Der Einsatz von Clopidogrel bei Patienten mit akutem Koronarsyndromen, nach perkutaner koronarer Intervention und Stentimplantation. *J Kardiolog* 2006;13:168-174.
540. Drexel H. Ezetrol: Die Fakten. *J Kardiolog* 2005;12:9-10.
541. Drexel H. Neue Argumente und Strategien zur Behandlung des HDL-Cholesterins. *J Kardiolog* 2005;12:12-14.
542. Aczel S, Marte T, Drexel H. Modulation der Blutfette durch körperliche Bewegung. *J Kardiolog* 2004;11:399-402.
543. Marte T, Drexel H. Lipidsenker bei Hypertonie - Was besagt die Evidenz? *J Hypertonie* 2004;8:7-10.
544. Drexel H. Niedriges HDL: ein koronarer Risikofaktor? *J Kardiolog* 2004;11:5-6.
545. Drexel H. Hohes HDL schützt vor Atherosklerose. *Med Trib* 2004;50:12.
546. Drexel H. The role of hyperlipidaemia in peripheral arterial occlusive disease. *J Kardiolog* 2003;10:146-148.
547. Drexel H, Marte T. Gemeinsame Präventionsstrategien bei Herzinfarkt und Schlaganfall? *Panvascular* 2003;4:6-9.